Amedeo Smart

Free Medical Literature Service


 

Amedeo

Ischemic Heart Disease

  Free Subscription

Articles published in
Am Heart J
    July 2021
  1. HSU B, Carcel C, Wang X, Peters SAE, et al
    Sex differences in emergency medical services management of patients with myocardial infarction: analysis of routinely collected data for over 110,000 patients.
    Am Heart J. 2021 Jul 24. pii: S0002-8703(21)00188.
    >> Share

    June 2021
  2. YONG CM, Spinelli KJ, Chiu ST, Jones B, et al
    Cardiovascular Procedural Deferral and Outcomes over COVID-19 Pandemic Phases: A Multi-Center Study.
    Am Heart J. 2021 Jun 25. pii: S0002-8703(21)00167.
    >> Share

  3. FERNANDEZ-ALVIRA JM, Fernandez-Jimenez R, de Miguel M, Santos-Beneit G, et al
    The challenge of sustainability: long-term results from the Fifty-Fifty peer group-based intervention in cardiovascular risk factors.
    Am Heart J. 2021 Jun 17. pii: S0002-8703(21)00162.
    >> Share

  4. COTTER G, Davison BA, Edwards C, Senger S, et al
    Regional variation of effects of new antidiabetic medications in cardiovascular outcome trials.
    Am Heart J. 2021 Jun 6. pii: S0002-8703(21)00148.
    >> Share

  5. PICICHE M, Biondi-Zoccai G, Del Prete A, Versaci F, et al
    "Effect of permanent right internal mammary artery occlusion on right coronary artery supply: A randomized placebo-controlled clinical trial".
    Am Heart J. 2021;236:100-101.
    >> Share

    May 2021
  6. BAJAJ R, Parasa R, Ramasamy A, Makariou N, et al
    Computerized technologies informing cardiac catheterization and guiding coronary intervention.
    Am Heart J. 2021 May 30. pii: S0002-8703(21)00146.
    >> Share

  7. MONEY JE, Muhlestein JB, Mason S, Bair TL, et al
    Simplifying the ISCHEMIA Trial Algorithm for Clinical Practice: Identifying Left Main Coronary Artery Disease Using Coronary Artery Calcium Scans.
    Am Heart J. 2021 May 26. pii: S0002-8703(21)00142.
    >> Share

  8. TINTUT Y, Demer LL
    Potential Impact of the Steroid Hormone, Vitamin D, on the Vasculature Vitamin D-hormones and cardiovascular disease.
    Am Heart J. 2021 May 26. pii: S0002-8703(21)00141.
    >> Share

  9. SLAVIN SD, Khera R, Zafar SY, Nasir K, et al
    Financial Burden, Distress and Toxicity in Cardiovascular Disease.
    Am Heart J. 2021 May 4. pii: S0002-8703(21)00113.
    >> Share

  10. YERASI C, Case BC, Chezar-Azerrad C, Forrestal BJ, et al
    Cangrelor vs. Glycoprotein IIb/IIIa Inhibitors During Percutaneous Coronary Intervention.
    Am Heart J. 2021 May 4. pii: S0002-8703(21)00115.
    >> Share

  11. MADSEN JMM, Jacobsen MRR, Sabbah M, Topal DGG, et al
    Long-Term Prognostic Outcomes and Implication of Oral Anticoagulants in Patients with New-Onset Atrial Fibrillation following ST-Segment Elevation Myocardial Infarction.
    Am Heart J. 2021 May 3. pii: S0002-8703(21)00114.
    >> Share

  12. SIDEBOTTOM AC, Miedema MD, Benson G, Vacquier M, et al
    The Impact of a Population-based Prevention Program on Cardiovascular Events: Findings from the Heart of New Ulm Project.
    Am Heart J. 2021 May 3. pii: S0002-8703(21)00112.
    >> Share

  13. SHI X, He J, Lin M, Liu C, et al
    Comparative effectiveness of team-based care with a clinical decision support system versus team-based care alone on cardiovascular risk reduction among patients with diabetes: Rationale and design of the D4C trial.
    Am Heart J. 2021 May 3. pii: S0002-8703(21)00111.
    >> Share

  14. ZANCHIN C, Koskinas KC, Ueki Y, Losdat S, et al
    Effects of the PCSK9 Antibody Alirocumab on Coronary Atherosclerosis in Patients with Acute Myocardial Infarction: A Serial, Multivessel, Intravascular Ultrasound, Near-Infrared Spectroscopy and Optical Coherence Tomography Imaging Study Rationale and
    Am Heart J. 2021 May 2. pii: S0002-8703(21)00108.
    >> Share

    April 2021
  15. SINGH H, Mehta RH, O'Neill W, Kapur NK, et al
    Clinical Features and Outcomes in Patients with Cardiogenic Shock Complicating Acute Myocardial Infarction: Early versus Recent Experience with Impella.
    Am Heart J. 2021 Apr 10. pii: S0002-8703(21)00090.
    >> Share

    March 2021
  16. KITKUNGVAN D, Johnson NP, Kirkeeide R, Haynie M, et al
    Design and Rationale of The Randomized Trial of Comprehensive LifEstyle ModificatioN, Optimal Pharmacological Treatment and Utilizing PET Imaging for Quantifying and Managing Stable CoronaRy ArterY Disease (The CENTURY Study).
    Am Heart J. 2021 Mar 21. pii: S0002-8703(21)00078.
    >> Share

  17. FUJISAKI T, Kuno T, Ando T, Briasoulis A, et al
    Potent P2Y12 Inhibitors versus Clopidogrel in Elderly Patients with Acute Coronary Syndrome: Systematic Review and Meta-Analysis: P2Y12 inhibitors and elderly patients with ACS.
    Am Heart J. 2021 Mar 15. pii: S0002-8703(21)00075.
    >> Share

  18. ETMINAN M, Brophy JM, Collins G, Nazemipour M, et al
    Curriculum in Cardiology To Adjust or Not to Adjust: The Role of Different Covariates in Cardiovascular Observational Studies.
    Am Heart J. 2021 Mar 12. pii: S0002-8703(21)00073.
    >> Share

  19. HOLLINGSWORTH R, Palmu A, Pepin S, Dupuy M, et al
    Effectiveness of the quadrivalent high-dose influenza vaccine for prevention of cardiovascular and respiratory events in people aged 65 years and above: rationale and design of a real-world pragmatic randomized clinical trial.
    Am Heart J. 2021 Mar 12. pii: S0002-8703(21)00072.
    >> Share

  20. ALFREDSSON J, James SK, Erlinge D, Herlitz J, et al
    Randomized comparison of early supplemental oxygen versus ambient air in patients with confirmed myocardial infarction: Sex related outcomes from DETO2X-AMI.
    Am Heart J. 2021 Mar 6. pii: S0002-8703(21)00066.
    >> Share

  21. QU J, Du J, Rao C, Chen S, et al
    Effect of a Smartphone-Based Intervention on Secondary Prevention Medication Prescriptions After Coronary Artery Bypass Graft Surgery: The MISSION-1 Randomized Controlled Trial.
    Am Heart J. 2021 Mar 6. pii: S0002-8703(21)00070.
    >> Share

  22. FABRIS E, Ten Berg JM, Hermanides RS, Ottervanger JP, et al
    NT-proBNP level before primary PCI and risk of poor myocardial reperfusion: Insight from the On-TIME II trial.
    Am Heart J. 2021;233:78-85.
    >> Share

    February 2021
  23. AKAO M, Yasuda S, Kaikita K, Ako J, et al
    Rivaroxaban Monotherapy versus Combination Therapy According to Patient Risk of Stroke and Bleeding in Atrial Fibrillation and Stable Coronary Disease: AFIRE trial sub-analysis.
    Am Heart J. 2021 Feb 28. pii: S0002-8703(21)00063.
    >> Share

  24. BATCHELOR WB, Damluji AA, Yong C, Fiuzat M, et al
    DOES STUDY SUBJECT DIVERSITY INFLUENCE CARDIOLOGY RESEARCH SITE PERFORMANCE?: INSIGHTS FROM 2 U.S. NATIONAL CORONARY STENT REGISTRIES.
    Am Heart J. 2021 Feb 23. pii: S0002-8703(21)00035.
    >> Share

  25. SUZUKI T, Salzano A, Israr MZ
    Targeting the gut microbiome in coronary artery disease.
    Am Heart J. 2021 Feb 22. pii: S0002-8703(21)00056.
    >> Share

  26. TANG WHW, Li XS, Wu Y, Wang Z, et al
    Plasma trimethylamine N-oxide (TMAO) levels predict future risk of coronary artery disease in apparently healthy individuals in the EPIC-Norfolk Prospective Population Study.
    Am Heart J. 2021 Feb 21. pii: S0002-8703(21)00057.
    >> Share

  27. GE Z, Gao XF, Kan J, Kong XQ, et al
    Comparison of 1-month Versus 12-month Dual Antiplatelet Therapy after Implantation of Drug-eluting Stents Guided by either Intravascular Ultrasound or Angiography in Patients with Acute Coronary Syndrome: Rationale and Design of Prospective, Multicent
    Am Heart J. 2021 Feb 20. pii: S0002-8703(21)00053.
    >> Share

  28. SHAHZEB KHAN M, Kristensen SL, Vaduganathan M, Kober L, et al
    Natriuretic Peptide Plasma Concentrations and Risk of Cardiovascular Versus Non-Cardiovascular Events in Heart Failure with Reduced Ejection Fraction Insights from the PARADIGM-HF and ATMOSPHERE Trials.
    Am Heart J. 2021 Feb 20. pii: S0002-8703(21)00054.
    >> Share

  29. PILGRIM T, Rothenbuhler M, Siontis GC, Kandzari DE, et al
    Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in patients undergoing percutaneous coronary intervention: a meta-analysis of individual patient data from five randomized trials.
    Am Heart J. 2021 Feb 17. pii: S0002-8703(21)00048.
    >> Share

  30. BEVAN GH, Freedman DA, Lee EK, Rajagopalan S, et al
    Association between Ambient Air Pollution and County-Level Cardiovascular Mortality in the United States by Social Deprivation Index.
    Am Heart J. 2021 Feb 13. pii: S0002-8703(21)00037.
    >> Share

  31. CAPELL WH, Barnathan ES, Piazza G, Spyropoulos AC, et al
    Rationale and Design for the Study of Rivaroxaban to Reduce Thrombotic Events, Hospitalization and Death in Outpatients with COVID-19: the PREVENT-HD Study.
    Am Heart J. 2021 Feb 9. pii: S0002-8703(21)00033.
    >> Share

  32. PRABHU KM, Don C, Sayre GG, Kearney KE, et al
    Interventional Cardiologists' Perceptions of Percutaneous Coronary Intervention Quality Measurement and Feedback.
    Am Heart J. 2021 Feb 7. pii: S0002-8703(21)00032.
    >> Share

  33. BROPHY TJ, Warsavage TJ, Hebbe AL, Plomondon ME, et al
    Percutaneous Coronary Intervention in Patients with Stable Coronary Artery Disease and Left Ventricular Systolic Dysfunction: Insights from the VA CART Program.
    Am Heart J. 2021 Feb 7. pii: S0002-8703(21)00034.
    >> Share

  34. JENTZER JC, Ahmed AM, Vallabhajosyula S, Burstein B, et al
    Shock in the cardiac intensive care unit: Changes in epidemiology and prognosis over time.
    Am Heart J. 2021;232:94-104.
    >> Share

  35. BRAIK N, Guedeney P, Behnes M, Desch S, et al
    Impact of chronic total occlusion and revascularization strategy in patients with infarct-related cardiogenic shock: A subanalysis of the culprit-shock trial.
    Am Heart J. 2021;232:185-193.
    >> Share

  36. SNAVELY AC, Hendley N, Stopyra JP, Lenoir KM, et al
    Sex and race differences in safety and effectiveness of the HEART pathway accelerated diagnostic protocol for acute chest pain.
    Am Heart J. 2021;232:125-136.
    >> Share

    January 2021
  37. AMBROSY AP, Malik UI, Thomas RC, Parikh RV, et al
    Rationale and Design of the Pragmatic Randomized Trial of Icosapent Ethyl for High Cardiovascular Risk Adults (MITIGATE).
    Am Heart J. 2021 Jan 28. pii: S0002-8703(21)00031.
    >> Share

  38. OLIVEIRA RS, Schneider BC, Callo-Quinte G, Oliveira IO, et al
    Prevalence of ideal cardiovascular health in young adults: A birth cohort from southern Brazil.
    Am Heart J. 2021 Jan 25. pii: S0002-8703(21)00018.
    >> Share

  39. SAWANO M, Spertus JA, Masoudi FA, Rumsfeld JS, et al
    Bleeding Avoidance Strategies and Percutaneous Coronary Intervention Outcomes: A Ten-year Observation from a Japanese Multicenter Registry: Post-PCI Bleeding Avoidance and Outcomes.
    Am Heart J. 2021 Jan 17. pii: S0002-8703(21)00014.
    >> Share

  40. GE Z, Kan J, Gao XF, Kong XQ, et al
    Comparison of intravascular ultrasound-guided with angiography-guided double kissing crush stenting for patients with complex coronary bifurcation lesions: rationale and design of a prospective, randomized and multicenter DKCRUSH VIII trial.
    Am Heart J. 2021 Jan 16. pii: S0002-8703(21)00015.
    >> Share

  41. ZHAO Y, Sivaswamy A, Lee MK, Izadnegahdar M, et al
    A Feasibility Study for CODE-MI: High-Sensitivity Cardiac Troponin - Optimizing the Diagnosis of Acute Myocardial Infarction/Injury in Women.
    Am Heart J. 2021 Jan 15. pii: S0002-8703(21)00012.
    >> Share

  42. ADACHI Y, Yamamoto M, Shimura T, Yamaguchi R, et al
    Late kidney injury after transcatheter aortic valve replacement.
    Am Heart J. 2021 Jan 14. pii: S0002-8703(21)00011.
    >> Share

  43. YANKEY GS, Jackson LR, Marts C, Chiswell K, et al
    African American-Caucasian American Differences in Aortic Valve Replacement in Patients with Severe Aortic Stenosis: Racial Differences in AVR.
    Am Heart J. 2021 Jan 13. pii: S0002-8703(21)00009.
    >> Share

  44. THIELE H, Freund A, Gimenez MR, de Waha-Thiele S, et al
    Extracorporeal life support in patients with acute myocardial infarction complicated by cardiogenic shock - Design and rationale of the ECLS-SHOCK trial.
    Am Heart J. 2021 Jan 8. pii: S0002-8703(21)00004.
    >> Share

  45. MARBACH JA, Wells G, Santo PD, So D, et al
    Acute Kidney Injury after Radial or Femoral Artery Access in ST-Segment Elevation Myocardial Infarction: AKI-SAFARI.
    Am Heart J. 2021 Jan 7. pii: S0002-8703(21)00001.
    >> Share

  46. FAGEL ND, Amoroso G, Vink MA, Slagboom T, et al
    An immediate or early invasive strategy in non-ST-elevation acute coronary syndrome: the OPTIMA-2 randomized controlled trial.
    Am Heart J. 2021 Jan 7. pii: S0002-8703(21)00003.
    >> Share

  47. BAO X, Borne Y, Xu B, Orho-Melander M, et al
    Growth differentiation factor-15 is a biomarker for all-cause mortality but less evident for cardiovascular outcomes: a prospective study: Abbreviated title: GDF-15, all-cause mortality and CVD.
    Am Heart J. 2021 Jan 6. pii: S0002-8703(21)00002.
    >> Share

  48. TOMASDOTTIR M, Held C, Hadziosmanovic N, Westerbergh J, et al
    Risk Markers of Incident Atrial Fibrillation in Patients with Coronary Heart Disease.
    Am Heart J. 2021 Jan 2. pii: S0002-8703(20)30425.
    >> Share

  49. SMILOWITZ NR, Subashchandran V, Yuriditsky E, Horowitz JM, et al
    Thrombosis in hospitalized patients with viral respiratory infections versus COVID-19.
    Am Heart J. 2021;231:93-95.
    >> Share

  50. CIOFANI JL, Han D, Allahwala UK, Asrress KN, et al
    Internet search volume for chest pain during the COVID-19 pandemic.
    Am Heart J. 2021;231:157-159.
    >> Share

  51. LAURIDSEN MD, Moller JE, Kober L, Fosbol EL, et al
    Reply to: Letter to the editor: Breaking the trend in cardiogenic shock-From door-to-balloon to door-to-support.
    Am Heart J. 2021;231:161.
    >> Share

  52. XU J, Leung DY, Lo S
    Letter to the editor: Breaking the trend in cardiogenic shock-From door-to-balloon to door-to-support.
    Am Heart J. 2021;231:160.
    >> Share

  53. VALGIMIGLI M, Cao D, Makkar RR, Bangalore S, et al
    Design and rationale of the XIENCE short DAPT clinical program: An assessment of the safety of 3-month and 1-month DAPT in patients at high bleeding risk undergoing PCI with an everolimus-eluting stent.
    Am Heart J. 2021;231:147-156.
    >> Share

    December 2020
  54. SALAH HM, Al'Aref SJ, Khan MS, Al-Hawwas M, et al
    Effects of Sodium-Glucose Cotransporter 1 and 2 Inhibitors on Cardiovascular and Kidney Outcomes in Type 2 Diabetes: A Meta-analysis Update.
    Am Heart J. 2020 Dec 29. pii: S0002-8703(20)30406.
    >> Share

  55. MCCORD J, Hana A, Cook B, Hudson MP, et al
    The Role of Cardiac Testing with the 0/1-Hour High-Sensitivity Cardiac Troponin Algorithm Evaluating for Acute Myocardial Infarction.
    Am Heart J. 2020 Dec 26. pii: S0002-8703(20)30417.
    >> Share

  56. THANGAM M, Luke AA, Amin AP, Lasala J, et al
    Sociodemographic differences in utilization and outcomes for temporary cardiovascular mechanical support in the setting of cardiogenic shock.
    Am Heart J. 2020 Dec 23. pii: S0002-8703(20)30416.
    >> Share

  57. MALIK AO, Amin A, Kennedy K, Qintar M, et al
    Patient-centered contrast thresholds to reduce acute kidney injury in high-risk patients undergoing percutaneous coronary intervention.
    Am Heart J. 2020 Dec 23. pii: S0002-8703(20)30415.
    >> Share

  58. SARRAJU A, Li J, Cannon CP, Chang TI, et al
    Effects of Canagliflozin on Cardiovascular, Renal, and Safety Outcomes in Participants With Type 2 Diabetes and Chronic Kidney Disease According to History of Heart Failure: Results From the CREDENCE Trial.
    Am Heart J. 2020 Dec 20. pii: S0002-8703(20)30407.
    >> Share

  59. ZHEUTLIN AR, Caldwell DJ, Al Danaf J, Shah RU, et al
    Prevalence of Control Groups in Cardiovascular Clinical Trials: An Analysis of ClinicalTrials.gov from 2009 through 2019.
    Am Heart J. 2020 Dec 18. pii: S0002-8703(20)30405.
    >> Share

  60. NUCCIA M, Claudia M, Alice S, Guido T, et al
    Early intra-aortic balloon pump in acute decompensated heart failure complicated by cardiogenic shock: rationale and design of the randomized Altshock- 2 trial.
    Am Heart J. 2020 Dec 15. pii: S0002-8703(20)30399.
    >> Share

  61. WARRAICH HJ, Wolf SP, Troy J, Swetz KM, et al
    Differences Between Patients with Cardiovascular Disease and Cancer Referred for Palliative Care.
    Am Heart J. 2020 Dec 8. pii: S0002-8703(20)30398.
    >> Share

  62. CHOUDHARY R, Kumari V
    Aspirin versus P2Y12 inhibitor-based monotherapy after percutaneous coronary intervention.
    Am Heart J. 2020;230:99.
    >> Share

  63. SAMSKY MD, Krucoff MW, Morrow DA, Abraham WT, et al
    Cardiac safety research consortium "shock II" think tank report: Advancing practical approaches to generating evidence for the treatment of cardiogenic shock.
    Am Heart J. 2020;230:93-97.
    >> Share

  64. DE LA PAZ A, Orgel R, Hartsell SE, Pauley E, et al
    Getting cardiogenic shock patients to the right place-How initial intensive care unit triage decisions impact processes of care and outcomes.
    Am Heart J. 2020;230:66-70.
    >> Share

    November 2020
  65. OSTERGAARD L, Butt JH, Kragholm K, Schou M, et al
    Incidence of acute coronary syndrome during national lock-down: insights from nationwide data during the coronavirus disease 2019 (COVID-19) pandemic.
    Am Heart J. 2020 Nov 5. pii: S0002-8703(20)30371.
    >> Share

  66. DAYAN V, Myers P
    Comparing apples and oranges and adding inches to meters: Is this the way to conduct rigorous meta-analyses of PCI versus CABG in left main coronary disease?
    Am Heart J. 2020;229:180-181.
    >> Share

  67. KUNO T, Ueyama H, Rao SV, Cohen MG, et al
    Meta-analysis of PCI vs. CABG for left main disease revisited.
    Am Heart J. 2020;229:178-179.
    >> Share

  68. MORROW AJ, Ford TJ, Mangion K, Kotecha T, et al
    Rationale and design of the Medical Research Council's Precision Medicine with Zibotentan in Microvascular Angina (PRIZE) trial.
    Am Heart J. 2020;229:70-80.
    >> Share

    October 2020
  69. WARME J, Sundqvist M, Mars K, Aladellie L, et al
    Helicobacter pylori screening in clinical routine during hospitalization for acute myocardial infarction: Rational and feasibility.
    Am Heart J. 2020 Oct 31. pii: S0002-8703(20)30358.
    >> Share

  70. WOSIK J, Clowse MEB, Overton R, Adagarla B, et al
    Impact of the COVID-19 Pandemic on Patterns of Outpatient Cardiovascular Care.
    Am Heart J. 2020 Oct 30. pii: S0002-8703(20)30360.
    >> Share

  71. CHERTOW GM, Pergola PE, Agarwal R, Block GA, et al
    Cardiovascular Safety and Efficacy of Vadadust for the Treatment of Anemia in Non-Dialysis Dependent CKD: Design and Baseline Characteristics.
    Am Heart J. 2020 Oct 29. pii: S0002-8703(20)30354.
    >> Share

  72. NOWAK RM, Jacobsen G, Jr AL, Peacock WF, et al
    Outpatient versus Observation/Inpatient Management of Emergency Department Patients Rapidly Ruled-out for Acute Myocardial Infarction: Findings from the HIGH-US Study.
    Am Heart J. 2020 Oct 27. pii: S0002-8703(20)30353.
    >> Share

  73. VARSHNEY AS, Wang DE, Bhatt AS, Blood A, et al
    Characteristics of Clinical Trials Evaluating Cardiovascular Therapies for Coronavirus Disease 2019 Registered on ClinicalTrials.gov: A Cross Sectional Analysis.
    Am Heart J. 2020 Oct 26. pii: S0002-8703(20)30351.
    >> Share

  74. NORDENSKJOLD AM, Agewall S, Atar D, Baron T, et al
    Randomized evaluation of beta blocker and ACE-inhibitor/angiotensin receptor blocker treatment in patients with myocardial infarction with non-obstructive coronary arteries (MINOCA-BAT): Rationale and design.
    Am Heart J. 2020;231:96-104.
    >> Share

  75. SALAH HM, Al'Aref SJ, Khan MS, Al-Hawwas M, et al
    Effect of sodium-glucose cotransporter 2 inhibitors on cardiovascular and kidney outcomes-Systematic review and meta-analysis of randomized placebo-controlled trials.
    Am Heart J. 2020;232:10-22.
    >> Share

  76. NICHOLLS SJ, Lincoff AM, Bays HE, Cho L, et al
    Rationale and design of the CLEAR-outcomes trial: Evaluating the effect of Bempedoic acid on cardiovascular events in patients with statin intolerance.
    Am Heart J. 2020 Oct 23. pii: S0002-8703(20)30346.
    >> Share

  77. SHAVADIA JS, Wilson J, Edmonston D, Platt A, et al
    Statins and atherosclerotic cardiovascular outcomes in patients on incident dialysis and with atherosclerotic heart disease.
    Am Heart J. 2020 Oct 20. pii: S0002-8703(20)30341.
    >> Share

  78. GIBSON CM, Kastelein JJP, Phillips AT, Aylward PE, et al
    Rationale and design of ApoA-I event reducing in ischemic syndromes II (AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after acute myoc
    Am Heart J. 2020 Oct 13. pii: S0002-8703(20)30335.
    >> Share

  79. FANAROFF AC, Chen AY, van Diepen S, Mylod D, et al
    Association between intensive care unit utilization for patients with non-ST segment elevation myocardial infarction and patient experience.
    Am Heart J. 2020 Oct 9. pii: S0002-8703(20)30270.
    >> Share

  80. WIGGERS H, Kober L, Gislason G, Schou M, et al
    The DANish randomized, double-blind, placebo controlled trial in patients with chronic HEART failure (DANHEART): A 2 x 2 factorial trial of hydralazine-isosorbide dinitrate in patients with chronic heart failure (H-HeFT) and metformin in patients with
    Am Heart J. 2020 Oct 8. pii: S0002-8703(20)30276.
    >> Share

  81. PARADIES V, Zheng H, Bulluck H, Hausenloy DJ, et al
    Response to the letter to the editor regarding the study "Impact of time of onset of symptom of ST-segment elevation myocardial infarction on 1-year rehospitalization for heart failure and mortality" published in the American Heart Journal.
    Am Heart J. 2020;228:117-118.
    >> Share

  82. ROSSBERG N, Kirresh A, Ahmad M
    Letter to the editor regarding the study "Impact of time of onset of symptom of ST-segment elevation myocardial infarction on 1-year rehospitalization for heart failure and mortality" published in the American Heart Journal.
    Am Heart J. 2020;228:116.
    >> Share

  83. JAWITZ OK, Cox ML, Ranney D, Williams JB, et al
    Outcomes following revascularization with radial artery bypass grafts: Insights from the PREVENT-IV trial.
    Am Heart J. 2020;228:91-97.
    >> Share

  84. AGGARWAL R, Chiu N, Pankayatselvan V, Shen C, et al
    Prevalence of angina and use of medical therapy among US adults: A nationally representative estimate.
    Am Heart J. 2020;228:44-46.
    >> Share

  85. LI Y, Wang X, Bao D, Liao Z, et al
    Optimal antiplatelet therapy for prevention of gastrointestinal injury evaluated by ANKON magnetically controlled capsule endoscopy: Rationale and design of the OPT-PEACE trial.
    Am Heart J. 2020;228:8-16.
    >> Share

    September 2020
  86. SKI CF, King-Shier K, Thompson DR
    Women are dying unnecessarily from cardiovascular disease.
    Am Heart J. 2020 Sep 30. pii: S0002-8703(20)30266.
    >> Share

  87. GRUBB AF, Pumill CA, Greene SJ, Wu A, et al
    Tobacco smoking in patients with heart failure and coronary artery disease: A 20-year experience at Duke University medical center.
    Am Heart J. 2020 Sep 24. pii: S0002-8703(20)30264.
    >> Share

  88. ANGRAAL S, Caraballo C, Kahn P, Bhatnagar A, et al
    Geographical Affiliation with Top 10 NIH-Funded Academic Medical Centers and Differences Between Mortality from Cardiovascular Disease and Cancer.
    Am Heart J. 2020 Sep 17. pii: S0002-8703(20)30251.
    >> Share

  89. BIGLER MR, Stoller M, Tschannen C, Grossenbacher R, et al
    Effect of permanent right internal mammary artery occlusion on right coronary artery supply: A randomized placebo-controlled clinical trial.
    Am Heart J. 2020 Sep 16. pii: S0002-8703(20)30259.
    >> Share

  90. SHAIKH A, Ochani RK, Khan MS, Riaz H, et al
    Contribution of individual components to composite endpoints in contemporary cardiovascular randomized controlled trials.
    Am Heart J. 2020 Sep 14. pii: S0002-8703(20)30254.
    >> Share

    August 2020
  91. LAURIDSEN MD, Rorth R, Lindholm MG, Kjaergaard J, et al
    Trends in first-time hospitalization, management, and short-term mortality in acute myocardial infarction-related cardiogenic shock from 2005-2017: A nationwide cohort study.
    Am Heart J. 2020 Aug 27. pii: S0002-8703(20)30242.
    >> Share

  92. BISCAGLIA S, Guiducci V, Santarelli A, Santos IA, et al
    Physiology-guided revascularization versus optimal medical therapy of non-culprit lesions in elderly patients with myocardial infarction: Rationale and design of the FIRE trial.
    Am Heart J. 2020 Aug 18. pii: S0002-8703(20)30237.
    >> Share

  93. GUTIERREZ JA, Heizer GM, Jones WS, Rockhold FW, et al
    CYP2C19 status and risk of major adverse cardiovascular events in peripheral artery disease: Insights from the EUCLID Trial.
    Am Heart J. 2020;229:118-120.
    >> Share

  94. CHERY G, Kamp N, Kosinski AS, Schmidler GS, et al
    Prognostic value of myocardial fibrosis on cardiac magnetic resonance imaging in patients with ischemic cardiomyopathy: A systematic review.
    Am Heart J. 2020;229:52-60.
    >> Share

  95. KANG DY, Ahn JM, Park H, Lee PH, et al
    Comparison of optical coherence tomography-guided versus intravascular ultrasound-guided percutaneous coronary intervention: Rationale and design of a randomized, controlled OCTIVUS trial.
    Am Heart J. 2020;228:72-80.
    >> Share

  96. SHLOFMITZ E, Torguson R, Mintz GS, Zhang C, et al
    The IMPact on Revascularization Outcomes of intraVascular ultrasound-guided treatment of complex lesions and Economic impact (IMPROVE) trial: Study design and rationale.
    Am Heart J. 2020;228:65-71.
    >> Share

  97. ELHARRAM M, Sharma A, White W, Bakris G, et al
    Timing of randomization after an acute coronary syndrome in patients with type 2 diabetes mellitus.
    Am Heart J. 2020;229:40-51.
    >> Share

  98. MUHLESTEIN JB, Muhlestein JB, Anderson JL, Bethea CF, et al
    Smartphone 12-lead ECG-Exciting but must be handled with care.
    Am Heart J. 2020;226:269.
    >> Share

  99. KATZ JN
    Back to the future-Are we ready for a randomized trial of surgical versus percutaneous revascularization in cardiogenic shock?
    Am Heart J. 2020;226:264-266.
    >> Share

  100. LINDOW T, Pahlm O
    Smartphone 12-lead ECG-Exciting but must be handled with care.
    Am Heart J. 2020;226:267-268.
    >> Share

    July 2020
  101. STAHLI BE, Varbella F, Schwarz B, Nordbeck P, et al
    Rationale and design of the MULTISTARS AMI Trial: A randomized comparison of immediate versus staged complete revascularization in patients with ST-segment elevation myocardial infarction and multivessel disease.
    Am Heart J. 2020;228:98-108.
    >> Share

  102. RYAN DH, Lingvay I, Colhoun HM, Deanfield J, et al
    Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design.
    Am Heart J. 2020;229:61-69.
    >> Share

  103. PLOUMEN EH, Buiten RA, Doggen CJM, Stoel MG, et al
    New-generation drug-eluting coronary stents in octogenarians: Patient-level pooled analysis from the TWENTE I-IV trials.
    Am Heart J. 2020;228:109-115.
    >> Share

  104. LI Y, Jing Q, Wang B, Wang X, et al
    Extended antiplatelet therapy with clopidogrel alone versus clopidogrel plus aspirin after completion of 9- to 12-month dual antiplatelet therapy for acute coronary syndrome patients with both high bleeding and ischemic risk. Rationale and design of t
    Am Heart J. 2020;228:1-7.
    >> Share

  105. YU C, Liu C, Du J, Liu H, et al
    Smartphone-based application to improve medication adherence in patients after surgical coronary revascularization.
    Am Heart J. 2020;228:17-26.
    >> Share

  106. SILVAIN J, Cayla G, Beygui F, Range G, et al
    Blunting periprocedural myocardial necrosis: Rationale and design of the randomized ALPHEUS study.
    Am Heart J. 2020;225:27-37.
    >> Share

    June 2020
  107. ZHAO Y, Izadnegahdar M, Lee MK, Kavsak PA, et al
    High-Sensitivity Cardiac Troponin-Optimizing the Diagnosis of Acute Myocardial Infarction/Injury in Women (CODE-MI): Rationale and design for a multicenter, stepped-wedge, cluster-randomized trial.
    Am Heart J. 2020;229:18-28.
    >> Share

  108. YAN Y, Wang X, Guo J, Li Y, et al
    Rationale and design of the RIGHT trial: A multicenter, randomized, double-blind, placebo-controlled trial of anticoagulation prolongation versus no anticoagulation after primary percutaneous coronary intervention for ST-segment elevation myocardial i
    Am Heart J. 2020;227:19-30.
    >> Share

  109. XU Y, Li X, Zhang H, Wu Y, et al
    China Tongxinluo Study for myocardial protection in patients with Acute Myocardial Infarction (CTS-AMI): Rationale and design of a randomized, double-blind, placebo-controlled, multicenter clinical trial.
    Am Heart J. 2020;227:47-55.
    >> Share

  110. PRASAD A, Panhwar S, Hendel RC, Sheikh O, et al
    COVID-19 and the cardiovascular system: A review of current data, summary of best practices, outline of controversies, and illustrative case reports.
    Am Heart J. 2020;226:174-187.
    >> Share

  111. KUNO T, Ueyama H, Takagi H, Bangalore S, et al
    P2Y12 inhibitor monotherapy versus aspirin monotherapy after short-term dual antiplatelet therapy for percutaneous coronary intervention: Insights from a network meta-analysis of randomized trials.
    Am Heart J. 2020;227:82-90.
    >> Share

  112. DEN DEKKER WK, Van Mieghem NM, Bennett J, Sabate M, et al
    Percutaneous complete revascularization strategies using sirolimus-eluting biodegradable polymer-coated stents in patients presenting with acute coronary syndrome and multivessel disease: Rationale and design of the BIOVASC trial.
    Am Heart J. 2020;227:111-117.
    >> Share

  113. KUNO T, Ueyama H, Rao SV, Cohen MG, et al
    Percutaneous coronary intervention or coronary artery bypass graft surgery for left main coronary artery disease: A meta-analysis of randomized trials.
    Am Heart J. 2020;227:9-10.
    >> Share

  114. HERTZ JT, Sakita FM, Kweka GL, Limkakeng AT, et al
    Acute myocardial infarction under-diagnosis and mortality in a Tanzanian emergency department: A prospective observational study.
    Am Heart J. 2020;226:214-221.
    >> Share

  115. ERHUN F, Kaplan RS, Narayanan VG, Brayton K, et al
    Are cost advantages from a modern Indian hospital transferable to the United States?
    Am Heart J. 2020;224:148-155.
    >> Share

    May 2020
  116. GIBBS J, deFilippi C, Peacock F, Mahler S, et al
    The utility of risk scores when evaluating for acute myocardial infarction using high-sensitivity cardiac troponin I.
    Am Heart J. 2020;227:1-8.
    >> Share

  117. BRAITEH N, Rehman WU, Alom M, Skovira V, et al
    Decrease in acute coronary syndrome presentations during the COVID-19 pandemic in upstate New York.
    Am Heart J. 2020;226:147-151.
    >> Share

  118. DEHGHANI P, Davidson LJ, Grines CL, Nayak K, et al
    North American COVID-19 ST-segment elevation myocardial infarction (NACMI) registry: Rationale, design, and implications.
    Am Heart J. 2020 May 16. pii: S0002-8703(20)30142.
    >> Share

  119. KUNO T, Takahashi M, Obata R, Maeda T, et al
    Cardiovascular comorbidities, cardiac injury and prognosis of COVID-19 in New York City.
    Am Heart J. 2020 May 15. pii: S0002-8703(20)30141.
    >> Share

  120. ARMSTRONG PW, Bogaerts K, Welsh R, Sinnaeve PR, et al
    The Second Strategic Reperfusion Early After Myocardial Infarction (STREAM-2) study optimizing pharmacoinvasive reperfusion strategy in older ST-elevation myocardial infarction patients.
    Am Heart J. 2020;226:140-146.
    >> Share

  121. BOTTINOR WJ, Soslow JH, Godown J, Stoddard MF, et al
    Childhood cancer survivors: The integral role of the cardiologist and cardiovascular imaging.
    Am Heart J. 2020;226:127-139.
    >> Share

  122. ABDELAZIZ HK, Abdelrahman A, Nabi A, Debski M, et al
    Impact of COVID-19 pandemic on patients with ST-segment elevation myocardial infarction: Insights from a British cardiac center.
    Am Heart J. 2020;226:45-48.
    >> Share

  123. CORTESE B
    COVID-19 pandemic-Some cardiovascular considerations from the trench.
    Am Heart J. 2020;225:1-2.
    >> Share

  124. FRANCO F, Alessandro Z, Carlo C, Domenico M, et al
    Impact of COVID-19 epidemic on coronary care unit accesses for acute coronary syndrome in Veneto region, Italy.
    Am Heart J. 2020;226:26-28.
    >> Share

  125. MOSHER CL, Mentz RJ
    Cardiovascular implications of idiopathic pulmonary fibrosis: A way forward together?
    Am Heart J. 2020;226:69-74.
    >> Share

  126. LOUNGANI RS, Rehorn MR, Newby LK, Katz JN, et al
    A care pathway for the cardiovascular complications of COVID-19: Insights from an institutional response.
    Am Heart J. 2020;225:3-9.
    >> Share

  127. SMILOWITZ NR, Galloway AC, Ohman EM, Rao SV, et al
    Coronary revascularization and circulatory support strategies in patients with myocardial infarction, multi-vessel coronary artery disease, and cardiogenic shock: Insights from an international survey.
    Am Heart J. 2020;225:55-59.
    >> Share

  128. LANG JP, Wang X, Moura FA, Siddiqi HK, et al
    A current review of COVID-19 for the cardiovascular specialist.
    Am Heart J. 2020;226:29-44.
    >> Share

  129. AE R, Abrams JY, Maddox RA, Schonberger LB, et al
    Outcomes in Kawasaki disease patients with coronary artery abnormalities at admission.
    Am Heart J. 2020;225:120-128.
    >> Share

    April 2020
  130. GUEDENEY P, Thiele H, Kerneis M, Barthelemy O, et al
    Radial versus femoral artery access for percutaneous coronary artery intervention in patients with acute myocardial infarction and multivessel disease complicated by cardiogenic shock: Subanalysis from the CULPRIT-SHOCK trial.
    Am Heart J. 2020;225:60-68.
    >> Share

  131. LAINE M, Lemesle G, Burtey S, Cayla G, et al
    TicagRelor Or Clopidogrel in severe or terminal chronic kidney patients Undergoing PERcutaneous coronary intervention for acute coronary syndrome: The TROUPER trial.
    Am Heart J. 2020;225:19-26.
    >> Share

  132. KEREIAKES DJ, Hill JM, Ben-Yehuda O, Maehara A, et al
    Evaluation of safety and efficacy of coronary intravascular lithotripsy for treatment of severely calcified coronary stenoses: Design and rationale for the Disrupt CAD III trial.
    Am Heart J. 2020;225:10-18.
    >> Share

  133. WHITE HD, Stewart RAH, Dalby AJ, Stebbins A, et al
    In patients with stable coronary heart disease, low-density lipoprotein-cholesterol levels < 70 mg/dL and glycosylated hemoglobin A1c <7% are associated with lower major cardiovascular events.
    Am Heart J. 2020;225:97-107.
    >> Share

  134. GALES J, Krasuski RA, Awerbach JD
    Emergency department evaluation of chest pain among adult congenital heart disease patients.
    Am Heart J. 2020;222:191-198.
    >> Share

  135. STEGEHUIS VE, Wijntjens GWM, van de Hoef TP, Casadonte L, et al
    Distal Evaluation of Functional performance with Intravascular sensors to assess the Narrowing Effect-combined pressure and Doppler FLOW velocity measurements (DEFINE-FLOW) trial: Rationale and trial design.
    Am Heart J. 2020;222:139-146.
    >> Share

  136. HAUW-BERLEMONT C, Lamhaut L, Diehl JL, Andreotti C, et al
    EMERGEncy versus delayed coronary angiogram in survivors of out-of-hospital cardiac arrest with no obvious non-cardiac cause of arrest: Design of the EMERGE trial.
    Am Heart J. 2020;222:131-138.
    >> Share

    March 2020
  137. WU CM, Albert NM, Gluckman TJ, Lu D, et al
    Facilitating the identification of patients hospitalized for acute myocardial infarction and heart failure and the assessment of their readmission risk through the Patient Navigator Program.
    Am Heart J. 2020;224:77-84.
    >> Share

  138. YOON YH, Ahn JM, Kang DY, Park H, et al
    Pragmatic trial comparing routine versus no routine functional testing in high-risk patients who underwent percutaneous coronary intervention: Rationale and design of POST-PCI trial.
    Am Heart J. 2020;224:156-165.
    >> Share

  139. BODEN WE, Miller MG, McBride R, Harvey C, et al
    Testosterone concentrations and risk of cardiovascular events in androgen-deficient men with atherosclerotic cardiovascular disease.
    Am Heart J. 2020;224:65-76.
    >> Share

  140. PARADIES V, Zheng H, Chan MHH, Chan MYY, et al
    Impact of time of onset of symptom of ST-segment elevation myocardial infarction on 1-year rehospitalization for heart failure and mortality.
    Am Heart J. 2020;224:1-9.
    >> Share

  141. OSMAN M, Saleem M, Osman K, Kheiri B, et al
    Radial versus femoral access for percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction: Trial sequential analysis.
    Am Heart J. 2020;224:98-104.
    >> Share

  142. RAGNARSSON S, Janiec M, Modrau IS, Dreifaldt M, et al
    No-touch saphenous vein grafts in coronary artery surgery (SWEDEGRAFT): Rationale and design of a multicenter, prospective, registry-based randomized clinical trial.
    Am Heart J. 2020;224:17-24.
    >> Share

  143. SMILOWITZ NR, Alviar CL, Katz SD, Hochman JS, et al
    Coronary artery bypass grafting versus percutaneous coronary intervention for myocardial infarction complicated by cardiogenic shock.
    Am Heart J. 2020 Mar 12. pii: S0002-8703(20)30080.
    >> Share

  144. VLACHOJANNIS GJ, Vogel RF, Wilschut JM, Lemmert ME, et al
    COMPARison of pre-hospital CRUSHed vs. uncrushed Prasugrel tablets in patients with STEMI undergoing primary percutaneous coronary interventions: Rationale and design of the COMPARE CRUSH trial.
    Am Heart J. 2020;224:10-16.
    >> Share

  145. LAU G, Koh M, Kavsak PA, Schull MJ, et al
    Clinical outcomes for chest pain patients discharged home from emergency departments using high-sensitivity versus conventional cardiac troponin assays.
    Am Heart J. 2020;221:84-94.
    >> Share

  146. G TOTH G, Lansky A, Baumbach A, Kelbaek H, et al
    Validation of the all-comers design: Results of the TARGET-AC substudy.
    Am Heart J. 2020;221:148-154.
    >> Share

    February 2020
  147. DAUBERT MA, White JA, Al-Khalidi HR, Velazquez EJ, et al
    Cardiac remodeling after large ST-elevation myocardial infarction in the current therapeutic era.
    Am Heart J. 2020;223:87-97.
    >> Share

  148. PEARSON GD, Mensah GA, Rosenberg Y, Stoney CM, et al
    National Heart, Lung, and Blood Institute cardiovascular clinical trial perspective.
    Am Heart J. 2020;224:25-34.
    >> Share

  149. SONG L, Tu S, Sun Z, Wang Y, et al
    Quantitative flow ratio-guided strategy versus angiography-guided strategy for percutaneous coronary intervention: Rationale and design of the FAVOR III China trial.
    Am Heart J. 2020;223:72-80.
    >> Share

  150. JAWITZ OK, Gulack BC, Brennan JM, Thibault DP, et al
    Association of postoperative complications and outcomes following coronary artery bypass grafting.
    Am Heart J. 2020;222:220-228.
    >> Share

  151. QUESADA O, AlBadri A, Wei J, Shufelt C, et al
    Design, methodology and baseline characteristics of the Women's Ischemia Syndrome Evaluation-Coronary Vascular Dysfunction (WISE-CVD).
    Am Heart J. 2020;220:224-236.
    >> Share

  152. D'ASCENZO F, Biole C, Raposeiras-Roubin S, Gaido F, et al
    Average daily ischemic versus bleeding risk in patients with ACS undergoing PCI: Insights from the BleeMACS and RENAMI registries.
    Am Heart J. 2020;220:108-115.
    >> Share

    January 2020
  153. HOUSSANY-PISSOT S, Rosencher J, Allouch P, Bensouda C, et al
    Screening coronary artery disease with computed tomography angiogram should limit normal invasive coronary angiogram, regardless of pretest probability.
    Am Heart J. 2020 Jan 30. pii: S0002-8703(20)30034.
    >> Share

  154. VALLABHAJOSYULA S, Vallabhajosyula S, Burstein B, Ternus BW, et al
    Epidemiology of in-hospital cardiac arrest complicating non-ST-segment elevation myocardial infarction receiving early coronary angiography.
    Am Heart J. 2020;223:59-64.
    >> Share

  155. FOX KAA, Anand SS, Aboyans V, Cowie MR, et al
    Xarelto plus Acetylsalicylic acid: Treatment patterns and Outcomes in patients with Atherosclerosis (XATOA): Rationale and design of a prospective registry study to assess rivaroxaban 2.5 mg twice daily plus aspirin for prevention of atherothrombotic
    Am Heart J. 2020;222:166-173.
    >> Share

  156. ROMAGUERA R, Salinas P, Brugaletta S, Gomez-Lara J, et al
    Second-Generation Drug-Eluting Stents in Diabetes (SUGAR) trial: Rationale and study design.
    Am Heart J. 2020;222:174-182.
    >> Share

  157. JEONG YJ, Park K, Kim YD
    Comparison between ticagrelor and clopidogrel on myocardial blood flow in patients with acute coronary syndrome, using 13 N-ammonia positron emission tomography.
    Am Heart J. 2020;222:121-130.
    >> Share

  158. DUENGEN HD, Kim RJ, Zahger D, Orvin K, et al
    Effects of the chymase inhibitor fulacimstat on adverse cardiac remodeling after acute myocardial infarction-Results of the Chymase Inhibitor in Adverse Remodeling after Myocardial Infarction (CHIARA MIA) 2 trial.
    Am Heart J. 2020;224:129-137.
    >> Share

  159. TARDIF JC, Dube MP, Pfeffer MA, Waters DD, et al
    Study design of Dal-GenE, a pharmacogenetic trial targeting reduction of cardiovascular events with dalcetrapib.
    Am Heart J. 2020;222:157-165.
    >> Share

  160. KINNAIRD T, Gallagher S, Spratt JC, Ludman P, et al
    Complex high-risk and indicated percutaneous coronary intervention for stable angina: Does operator volume influence patient outcome?
    Am Heart J. 2020;222:15-25.
    >> Share

  161. DALGAARD F, North R, Pieper K, Fonarow GC, et al
    Risk of major cardiovascular and neurologic events with obstructive sleep apnea among patients with atrial fibrillation.
    Am Heart J. 2020;223:65-71.
    >> Share

  162. CASSESE S, Ndrepepa G, Byrne RA, Laugwitz KL, et al
    Ticagrelor-based antiplatelet regimens in patients with atherosclerotic artery disease-A meta-analysis of randomized clinical trials.
    Am Heart J. 2020;219:109-116.
    >> Share

  163. NANNA MG, Peterson ED, Wu A, Harding T, et al
    Age, knowledge, preferences, and risk tolerance for invasive cardiac care.
    Am Heart J. 2020;219:99-108.
    >> Share

  164. SAMSKY M, Krucoff M, Althouse AD, Abraham WT, et al
    Clinical and regulatory landscape for cardiogenic shock: A report from the Cardiac Safety Research Consortium ThinkTank on cardiogenic shock.
    Am Heart J. 2020;219:1-8.
    >> Share

    December 2019
  165. PUYMIRAT E, Simon T, de Bruyne B, Montalescot G, et al
    Rationale and design of the Flow Evaluation to Guide Revascularization in Multivessel ST-Elevation Myocardial Infarction (FLOWER-MI) trial.
    Am Heart J. 2019;222:1-7.
    >> Share

  166. MUHLESTEIN JB, Anderson JL, Bethea CF, Severance HW, et al
    Feasibility of combining serial smartphone single-lead electrocardiograms for the diagnosis of ST-elevation myocardial infarction.
    Am Heart J. 2019;221:125-135.
    >> Share

  167. KALRA R, Shenoy C
    Identifying nonischemic cardiomyopathy patients who would benefit from an implantable cardioverter-defibrillator: Can late gadolinium enhancement on cardiovascular magnetic resonance imaging help?
    Am Heart J. 2019 Dec 17. pii: S0002-8703(19)30352.
    >> Share

  168. SALAHUDDIN T, Kittelson J, Tardif JC, Shah PK, et al
    Association of high-density lipoprotein particle concentration with cardiovascular risk following acute coronary syndrome: A case-cohort analysis of the dal-Outcomes trial.
    Am Heart J. 2019;221:60-66.
    >> Share

  169. SHLOFMITZ E, Torguson R, Zhang C, Craig PE, et al
    Impact of Intravascular Ultrasound on Outcomes Following PErcutaneous Coronary InterventioN in Complex Lesions (iOPEN Complex).
    Am Heart J. 2019;221:74-83.
    >> Share

  170. WILLEMSEN LM, Janssen PWA, Hackeng CM, Kelder JC, et al
    A randomized, double-blind, placebo-controlled trial investigating the effect of ticagrelor on saphenous vein graft patency in patients undergoing coronary artery bypass grafting surgery-Rationale and design of the POPular CABG trial.
    Am Heart J. 2019;220:237-245.
    >> Share

  171. TRIPOLT NJ, Kolesnik E, Pferschy PN, Verheyen N, et al
    Impact of EMpagliflozin on cardiac function and biomarkers of heart failure in patients with acute MYocardial infarction-The EMMY trial.
    Am Heart J. 2019;221:39-47.
    >> Share

  172. PATEL DM, Thiessen-Philbrook H, Brown JR, McArthur E, et al
    Association of plasma-soluble ST2 and galectin-3 with cardiovascular events and mortality following cardiac surgery.
    Am Heart J. 2019;220:253-263.
    >> Share

  173. SIDIK NP, McEntegart M, Roditi G, Ford TJ, et al
    Rationale and design of the British Heart Foundation (BHF) Coronary Microvascular Function and CT Coronary Angiogram (CorCTCA) study.
    Am Heart J. 2019;221:48-59.
    >> Share

  174. MAZUREK M, Teutsch C, Diener HC, Dubner SJ, et al
    Safety and effectiveness of dabigatran at 2 years: Final outcomes from Phase II of the GLORIA-AF registry program.
    Am Heart J. 2019;218:123-127.
    >> Share

  175. RYMER JA, O'Donnell CI, Plomondon ME, Hess PL, et al
    Same-day discharge among patients undergoing elective PCI: Insights from the VA CART Program.
    Am Heart J. 2019;218:75-83.
    >> Share

    November 2019
  176. DE FERRARI GM, Stevens SR, Ambrosio G, Leonardi S, et al
    Low-density lipoprotein cholesterol treatment and outcomes in patients with type 2 diabetes and established cardiovascular disease: Insights from TECOS.
    Am Heart J. 2019;220:82-88.
    >> Share

  177. TOFLER GH, Morel-Kopp MC, Spinaze M, Dent J, et al
    The effect of metoprolol and aspirin on cardiovascular risk in bereavement: A randomized controlled trial.
    Am Heart J. 2019;220:264-272.
    >> Share

  178. YANG D, O'Brien CG, Ikeda G, Traverse JH, et al
    Meta-analysis of short- and long-term efficacy of mononuclear cell transplantation in patients with myocardial infarction.
    Am Heart J. 2019;220:155-175.
    >> Share

  179. SHAVADIA JS, Granger CB, Alemayehu W, Westerhout CM, et al
    High-throughput targeted proteomics discovery approach and spontaneous reperfusion in ST-segment elevation myocardial infarction.
    Am Heart J. 2019;220:137-144.
    >> Share

  180. LORING Z, Shrader P, Allen LA, Blanco R, et al
    Guideline-directed therapies for comorbidities and clinical outcomes among individuals with atrial fibrillation.
    Am Heart J. 2019;219:21-30.
    >> Share

    October 2019
  181. CANNON CP, de Lemos JA, Rosenson RS, Ballantyne CM, et al
    Getting to an ImprOved Understanding of Low-Density Lipoprotein-Cholesterol and Dyslipidemia Management (GOULD): Methods and baseline data of a registry of high cardiovascular risk patients in the United States.
    Am Heart J. 2019;219:70-77.
    >> Share

  182. JENTZER JC, Baran DA, van Diepen S, Barsness GW, et al
    Admission Society for Cardiovascular Angiography and Intervention shock stage stratifies post-discharge mortality risk in cardiac intensive care unit patients.
    Am Heart J. 2019;219:37-46.
    >> Share

  183. WELSH RC, Peterson ED, De Caterina R, Bode C, et al
    Applying contemporary antithrombotic therapy in the secondary prevention of chronic atherosclerotic cardiovascular disease.
    Am Heart J. 2019;218:100-109.
    >> Share

  184. CHLEBUS K, Zdrojewski T, Gruchala M, Galaska R, et al
    Cardiovascular risk factor profiles in familial hypercholesterolemia patients with and without genetic mutation compared to a nationally representative sample of adults in a high-risk European country.
    Am Heart J. 2019;218:32-45.
    >> Share

  185. RYMER JA, Mandawat A, Abbott JD, Cohen MG, et al
    Opportunities for enhancing the care of older patients with ST-elevation myocardial infarction presenting for primary percutaneous coronary intervention: Rationale and design of the SAFE-STEMI for Seniors trial.
    Am Heart J. 2019;218:84-91.
    >> Share

  186. SHAVADIA JS, Zheng Y, Green JB, Armstrong PW, et al
    Associations between beta-blocker therapy and cardiovascular outcomes in patients with diabetes and established cardiovascular disease.
    Am Heart J. 2019;218:92-99.
    >> Share

  187. PAGIDIPATI NJ, Zheng Y, Green JB, McGuire DK, et al
    Association of obesity with cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease: Insights from TECOS.
    Am Heart J. 2019;219:47-57.
    >> Share

  188. NIDORF SM, Fiolet ATL, Eikelboom JW, Schut A, et al
    The effect of low-dose colchicine in patients with stable coronary artery disease: The LoDoCo2 trial rationale, design, and baseline characteristics.
    Am Heart J. 2019;218:46-56.
    >> Share

  189. JONES WS, Kennedy KF, Hawkins BM, Attaran RR, et al
    Expanding opportunities to understand quality and outcomes of peripheral vascular interventions: The ACC NCDR PVI Registry.
    Am Heart J. 2019;216:74-81.
    >> Share

  190. CZOBOR P, Hung YY, Baer D, McGlothlin D, et al
    Amyloid cardiomyopathy in a large integrated health care system.
    Am Heart J. 2019;216:42-52.
    >> Share

    September 2019
  191. BRENNAN JM, Wruck L, Pencina MJ, Clare RM, et al
    Claims-based cardiovascular outcome identification for clinical research: Results from 7 large randomized cardiovascular clinical trials.
    Am Heart J. 2019;218:110-122.
    >> Share

  192. FERREIRA JP, Rossignol P, Dewan P, Lamiral Z, et al
    Income level and inequality as complement to geographical differences in cardiovascular trials.
    Am Heart J. 2019;218:66-74.
    >> Share

  193. LOWENSTERN A, Wu J, Bradley SM, Fanaroff AC, et al
    Current landscape of hybrid revascularization: A report from the NCDR CathPCI Registry.
    Am Heart J. 2019;215:167-177.
    >> Share

    August 2019
  194. PARK S, Ahn JM, Lee K, Kwon O, et al
    Long-term (10-year) outcomes of stenting or bypass surgery for acute coronary syndromes and stable ischemic heart disease with unprotected left main coronary artery disease.
    Am Heart J. 2019;218:9-19.
    >> Share

  195. DECKER PA, Larson NB, Bell EJ, Pankow JS, et al
    Erratum to "Increased hepatocyte growth factor levels over 2 years are associated with coronary heart disease: The Multi-Ethnic Study of Atherosclerosis (MESA)" [Am Heart J (2019) 30-34].
    Am Heart J. 2019 Aug 19. pii: S0002-8703(19)30176.
    >> Share

  196. PAUL S, Judd SE, Howard VJ, Safford MS, et al
    Association of 25-hydroxyvitamin D with incident coronary heart disease in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) study.
    Am Heart J. 2019;217:140-147.
    >> Share

  197. BRELLENTHIN AG, Lanningham-Foster LM, Kohut ML, Li Y, et al
    Comparison of the Cardiovascular Benefits of Resistance, Aerobic, and Combined Exercise (CardioRACE): Rationale, design, and methods.
    Am Heart J. 2019;217:101-111.
    >> Share

  198. CASTAGNO M, Menegon V, Monzani A, Zanetta S, et al
    Small-for-gestational-age birth is linked to cardiovascular dysfunction in early childhood.
    Am Heart J. 2019;217:84-93.
    >> Share

  199. RAY KK, Nicholls SJ, Ginsberg HD, Johansson JO, et al
    Effect of selective BET protein inhibitor apabetalone on cardiovascular outcomes in patients with acute coronary syndrome and diabetes: Rationale, design, and baseline characteristics of the BETonMACE trial.
    Am Heart J. 2019;217:72-83.
    >> Share

  200. VALENTE AM, Landzberg MJ, Gauvreau K, Egidy-Assenza G, et al
    Standardized outcomes in reproductive cardiovascular care: The STORCC initiative.
    Am Heart J. 2019;217:112-120.
    >> Share

  201. UDESEN NJ, Moller JE, Lindholm MG, Eiskjaer H, et al
    Rationale and design of DanGer shock: Danish-German cardiogenic shock trial.
    Am Heart J. 2019;214:60-68.
    >> Share

    July 2019
  202. TREBUCHET A, Julia C, Fezeu L, Touvier M, et al
    Prospective association between several dietary scores and risk of cardiovascular diseases: Is the Mediterranean diet equally associated to cardiovascular diseases compared to National Nutritional Scores?
    Am Heart J. 2019;217:1-12.
    >> Share

  203. RAMASAMY A, Serruys PW, Jones DA, Johnson TW, et al
    Reliable in vivo intravascular imaging plaque characterization: A challenge unmet.
    Am Heart J. 2019;218:20-31.
    >> Share

  204. SMILOWITZ NR, Lorin J, Berger JS
    Risks of noncardiac surgery early after percutaneous coronary intervention.
    Am Heart J. 2019;217:64-71.
    >> Share

  205. OKEKE NL, Webel AR, Bosworth HB, Aifah A, et al
    Rationale and design of a nurse-led intervention to extend the HIV treatment cascade for cardiovascular disease prevention trial (EXTRA-CVD).
    Am Heart J. 2019;216:91-101.
    >> Share

  206. MOK Y, Sang Y, Ballew SH, Hoogeveen RC, et al
    Premorbid levels of high-sensitivity cardiac troponin T and natriuretic peptide and prognosis after incident myocardial infarction.
    Am Heart J. 2019;216:62-73.
    >> Share

  207. MAURI L, Doros G, Rao SV, Cohen DJ, et al
    The OPTIMIZE randomized trial to assess safety and efficacy of the Svelte IDS and RX Sirolimus-eluting coronary stent Systems for the Treatment of atherosclerotic lesions: Trial design and rationale.
    Am Heart J. 2019;216:82-90.
    >> Share

  208. FARIDI KF, Rymer JA, Rao SV, Dai D, et al
    Ad hoc percutaneous coronary intervention in patients with stable coronary artery disease: A report from the National Cardiovascular Data Registry CathPCI Registry.
    Am Heart J. 2019;216:53-61.
    >> Share

  209. FU EL, Franko MA, Obergfell A, Dekker FW, et al
    High-sensitivity C-reactive protein and the risk of chronic kidney disease progression or acute kidney injury in post-myocardial infarction patients.
    Am Heart J. 2019;216:20-29.
    >> Share

  210. KONIGSTEIN M, Madhavan MV, Ben-Yehuda O, Rahim HM, et al
    Incidence and predictors of target lesion failure in patients undergoing contemporary DES implantation-Individual patient data pooled analysis from 6 randomized controlled trials.
    Am Heart J. 2019;213:105-111.
    >> Share

    June 2019
  211. WEBER B, Bersch-Ferreira AC, Torreglosa CR, Marcadenti A, et al
    Implementation of a Brazilian Cardioprotective Nutritional (BALANCE) Program for improvement on quality of diet and secondary prevention of cardiovascular events: A randomized, multicenter trial.
    Am Heart J. 2019;215:187-197.
    >> Share

  212. KUKULA K, Urbanowicz A, Klopotowski M, Dabrowski M, et al
    Long-term follow-up and safety assessment of angiogenic gene therapy trial VIF-CAD: Transcatheter intramyocardial administration of a bicistronic plasmid expressing VEGF-A165/bFGF cDNA for the treatment of refractory coronary artery disease.
    Am Heart J. 2019;215:78-82.
    >> Share

  213. JOSHI R, Agrawal T, Fathima F, Usha T, et al
    Cardiovascular risk factor reduction by community health workers in rural India: A cluster randomized trial.
    Am Heart J. 2019;216:9-19.
    >> Share

  214. MEHTA SR, Wood DA, Meeks B, Storey RF, et al
    Design and rationale of the COMPLETE trial: A randomized, comparative effectiveness study of complete versus culprit-only percutaneous coronary intervention to treat multivessel coronary artery disease in patients presenting with ST-segment elevation
    Am Heart J. 2019;215:157-166.
    >> Share

  215. HENNESSY T, Soh L, Bowman M, Kurup R, et al
    The Low Dose Colchicine after Myocardial Infarction (LoDoCo-MI) study: A pilot randomized placebo controlled trial of colchicine following acute myocardial infarction.
    Am Heart J. 2019;215:62-69.
    >> Share

  216. CABEZA DE BACA T, Burroughs Pena MS, Slopen N, Williams D, et al
    Financial strain and ideal cardiovascular health in middle-aged and older women: Data from the Women's health study.
    Am Heart J. 2019;215:129-138.
    >> Share

  217. HALL TS, von Lueder TG, Zannad F, Rossignol P, et al
    Left ventricular ejection fraction and adjudicated, cause-specific hospitalizations after myocardial infarction complicated by heart failure or left ventricular dysfunction.
    Am Heart J. 2019;215:83-90.
    >> Share

  218. CANNON CP, Khan I, Klimchak AC, Sanchez RJ, et al
    Simulation of impact on cardiovascular events due to lipid-lowering therapy intensification in a population with atherosclerotic cardiovascular disease.
    Am Heart J. 2019;216:30-41.
    >> Share

  219. GIBLETT JP, Clarke S, Zhao T, McCormick LM, et al
    The role of Glucagon-Like Peptide 1 Loading on periprocedural myocardial infarction During elective PCI (GOLD-PCI study): A randomized, placebo-controlled trial.
    Am Heart J. 2019;215:41-51.
    >> Share

  220. LENG W, Yang J, Fan X, Sun Y, et al
    Contemporary invasive management and in-hospital outcomes of patients with non-ST-segment elevation myocardial infarction in China: Findings from China Acute Myocardial Infarction (CAMI) Registry.
    Am Heart J. 2019;215:1-11.
    >> Share

  221. MANNER DH, Battioui C, Hantel S, Beasley BN, et al
    Restricted mean survival time for the analysis of cardiovascular outcome trials assessing non-inferiority: Case studies from antihyperglycemic drug development.
    Am Heart J. 2019;215:178-186.
    >> Share

  222. STROM JB, Tamez H, Zhao Y, Valsdottir LR, et al
    Validating the use of registries and claims data to support randomized trials: Rationale and design of the Extending Trial-Based Evaluations of Medical Therapies Using Novel Sources of Data (EXTEND) Study.
    Am Heart J. 2019;212:64-71.
    >> Share

    May 2019
  223. CLAEYS MJ, Coussement P, Dubois P, Garcia-Dorado D, et al
    Clinical effects of cyclosporine in acute anterior myocardial infarction complicated by heart failure: A subgroup analysis of the CIRCUS Trial.
    Am Heart J. 2019 May 30. pii: S0002-8703(19)30129.
    >> Share


  224. Correction to "Sex differences in long-term outcomes of patients across the spectrum of coronary artery disease", [American Heart Journal (December 2018) 51-60].
    Am Heart J. 2019 May 29. pii: S0002-8703(19)30112.
    >> Share

  225. MESSERLI M, Panadero AL, Giannopoulos AA, Schwyzer M, et al
    Enhanced radiation exposure associated with anterior-posterior x-ray tube position in young women undergoing cardiac computed tomography.
    Am Heart J. 2019;215:91-94.
    >> Share

  226. FANAROFF AC, Vora AN, Chen AY, Mathews R, et al
    Hospital participation in clinical trials for patients with acute myocardial infarction: Results from the National Cardiovascular Data Registry.
    Am Heart J. 2019;214:184-193.
    >> Share

  227. YING T, Gill J, Webster A, Kim SJ, et al
    Canadian-Australasian Randomised trial of screening kidney transplant candidates for coronary artery disease-A trial protocol for the CARSK study.
    Am Heart J. 2019;214:175-183.
    >> Share

  228. PUYMIRAT E, Cayla G, Cottin Y, Elbaz M, et al
    Twenty-year trends in profile, management and outcomes of patients with ST-segment elevation myocardial infarction according to use of reperfusion therapy: Data from the FAST-MI program 1995-2015.
    Am Heart J. 2019;214:97-106.
    >> Share

  229. TOTH G, Brodmann M, Barbato E, Mangiacapra F, et al
    Rational and design of the INtentional COronary revascularization versus conservative therapy in patients undergOing successful peripheRAl arTEry revascularization due to critical limb ischemia trial (INCORPORATE trial).
    Am Heart J. 2019;214:107-112.
    >> Share

  230. SHARMA A, Hagstrom E, Wojdyla DM, Neely ML, et al
    Clinical consequences of bleeding among individuals with a recent acute coronary syndrome: Insights from the APPRAISE-2 trial.
    Am Heart J. 2019;215:106-113.
    >> Share

  231. MENTIAS A, Shantha G, Adeola O, Barnes GD, et al
    Role of diabetes and insulin use in the risk of stroke and acute myocardial infarction in patients with atrial fibrillation: A Medicare analysis.
    Am Heart J. 2019;214:158-166.
    >> Share

  232. GAZIANO TA, Pandya A, Sy S, Jardim TV, et al
    Modeling the cost effectiveness and budgetary impact of Polypills for secondary prevention of cardiovascular disease in the United States.
    Am Heart J. 2019;214:77-87.
    >> Share

  233. GELMAN A, Carlin JB, Nallamothu BK
    Objective Randomised Blinded Investigation With Optimal Medical Therapy of Angioplasty in Stable Angina (ORBITA) and coronary stents: A case study in the analysis and reporting of clinical trials.
    Am Heart J. 2019;214:54-59.
    >> Share

  234. DOUCET S, Jolicoeur EM, Serruys PW, Ragosta M 3rd, et al
    Outcomes of left main revascularization in patients with acute coronary syndromes and stable ischemic heart disease: Analysis from the EXCEL trial.
    Am Heart J. 2019;214:9-17.
    >> Share

  235. RASMUSSEN LD, Winther S, Westra J, Isaksen C, et al
    Danish study of Non-Invasive testing in Coronary Artery Disease 2 (Dan-NICAD 2): Study design for a controlled study of diagnostic accuracy.
    Am Heart J. 2019;215:114-128.
    >> Share

  236. GUDNADOTTIR GS, James SK, Andersen K, Lagerqvist B, et al
    Outcomes after STEMI in old multimorbid patients with complex health needs and the effect of invasive management.
    Am Heart J. 2019;211:11-21.
    >> Share

    April 2019
  237. ZIMMERMANN FM, De Bruyne B, Pijls NHJ, Desai M, et al
    A protocol update of the Fractional Flow Reserve versus Angiography for Multivessel Evaluation (FAME) 3 trial: A comparison of fractional flow reserve-guided percutaneous coronary intervention and coronary artery bypass graft surgery in patients with
    Am Heart J. 2019;214:156-157.
    >> Share

  238. QINTAR M, Hirai T, Arnold SV, Sheehy J, et al
    De-escalation of antianginal medications after successful chronic total occlusion percutaneous coronary intervention: Frequency and relationship with health status.
    Am Heart J. 2019;214:1-8.
    >> Share

  239. VAN DEN BERG MJ, van der Graaf Y, Deckers JW, de Kanter W, et al
    Smoking cessation and risk of recurrent cardiovascular events and mortality after a first manifestation of arterial disease.
    Am Heart J. 2019;213:112-122.
    >> Share

  240. INOHARA T, Shrader P, Pieper K, Blanco RG, et al
    Treatment of atrial fibrillation with concomitant coronary or peripheral artery disease: Results from the outcomes registry for better informed treatment of atrial fibrillation II.
    Am Heart J. 2019;213:81-90.
    >> Share

  241. AKERBLOM A, Wojdyla DM, Wallentin L, James SK, et al
    Ticagrelor in patients with heart failure after acute coronary syndromes-Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial.
    Am Heart J. 2019;213:57-65.
    >> Share

  242. GUTIERREZ JA, Bhatt DL, Banerjee S, Glorioso TJ, et al
    Risk of obstructive coronary artery disease and major adverse cardiac events in patients with noncoronary atherosclerosis: Insights from the Veterans Affairs Clinical Assessment, Reporting, and Tracking (CART) Program.
    Am Heart J. 2019;213:47-56.
    >> Share

  243. SULLIVAN LT 2ND, Mulder H, Chiswell K, Shaw LK, et al
    Racial differences in long-term outcomes among black and white patients with drug-eluting stents.
    Am Heart J. 2019;214:46-53.
    >> Share

  244. DECKER PA, Larson NB, Bell EJ, Pankow JS, et al
    Increased hepatocyte growth factor levels over 2 years are associated with coronary heart disease: the Multi-Ethnic Study of Atherosclerosis (MESA).
    Am Heart J. 2019;213:30-34.
    >> Share

  245. YANDRAPALLI S, Sanaani A, Harikrishnan P, Aronow WS, et al
    Cardiogenic shock during heart failure hospitalizations: Age-, sex-, and race-stratified trends in incidence and outcomes.
    Am Heart J. 2019;213:18-29.
    >> Share

  246. VAN ZANDVOORT LJC, Masdjedi K, Tovar Forero MN, Lenzen MJ, et al
    Fractional flow reserve guided percutaneous coronary intervention optimization directed by high-definition intravascular ultrasound versus standard of care: Rationale and study design of the prospective randomized FFR-REACT trial.
    Am Heart J. 2019;213:66-72.
    >> Share

  247. VROEGINDEWEY MM, van den Berg VJ, Bouwens E, Akkerhuis KM, et al
    Temporal evolution of myeloperoxidase and galectin 3 during 1 year after acute coronary syndrome admission.
    Am Heart J. 2019 Apr 6. pii: S0002-8703(19)30052.
    >> Share

  248. HSU S
    Response to the letter to the editor regarding the results of the retrospective study "Predictors of intra-aortic balloon pump hemodynamic failure in non-acute myocardial infarction cardiogenic shock" published in the American Heart Journal.
    Am Heart J. 2019 Apr 6. pii: S0002-8703(19)30067.
    >> Share

    March 2019
  249. SACCO A, Morici N, Oliva F
    Letter to the editor regarding the results of the retrospective study "Predictors of intra-aortic balloon pump hemodynamic failure in non-acute myocardial infarction cardiogenic shock" published in the American Heart Journal.
    Am Heart J. 2019 Mar 23. pii: S0002-8703(19)30056.
    >> Share

  250. JENSEN LO, Maeng M, Raungaard B, Engstrom T, et al
    Comparison of the polymer-free biolimus-coated BioFreedom stent with the thin-strut biodegradable polymer sirolimus-eluting Orsiro stent in an all-comers population treated with percutaneous coronary intervention: Rationale and design of the randomize
    Am Heart J. 2019;213:1-7.
    >> Share

  251. XING Y, Liu J, Hao Y, Liu J, et al
    Prehospital statin use and low-density lipoprotein cholesterol levels at admission in acute coronary syndrome patients with history of myocardial infarction or revascularization: Findings from the Improving Care for Cardiovascular Disease in China (CC
    Am Heart J. 2019;212:120-128.
    >> Share

  252. PUMILL CA, Bush CG, Greiner MA, Hall ME, et al
    Neck circumference and cardiovascular outcomes: Insights from the Jackson Heart Study.
    Am Heart J. 2019;212:72-79.
    >> Share

  253. KIM C, Hong SJ, Shin DH, Kim BK, et al
    Randomized evaluation of ticagrelor monotherapy after 3-month dual-antiplatelet therapy in patients with acute coronary syndrome treated with new-generation sirolimus-eluting stents: TICO trial rationale and design.
    Am Heart J. 2019;212:45-52.
    >> Share

  254. ANGRAAL S, Gupta A, Khera R, Nasir K, et al
    Association of access to exercise opportunities and cardiovascular mortality.
    Am Heart J. 2019;212:152-156.
    >> Share

  255. YUDI MB, Clark DJ, Farouque O, Andrianopoulos N, et al
    Trends and predictors of recurrent acute coronary syndrome hospitalizations and unplanned revascularization after index acute myocardial infarction treated with percutaneous coronary intervention.
    Am Heart J. 2019;212:134-143.
    >> Share

  256. HOFFMANN U, Lu MT, Olalere D, Adami EC, et al
    Rationale and design of the Mechanistic Substudy of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE): Effects of pitavastatin on coronary artery disease and inflammatory biomarkers.
    Am Heart J. 2019;212:1-12.
    >> Share

  257. YANG N, Liu J, Liu J, Hao Y, et al
    Performance on management strategies with Class I Recommendation and A Level of Evidence among hospitalized patients with non-ST-segment elevation acute coronary syndrome in China: Findings from the Improving Care for Cardiovascular Disease in China-A
    Am Heart J. 2019;212:80-90.
    >> Share

  258. LIP GYH, Mauri L, Montalescot G, Ozkor M, et al
    Relationship of stroke and bleeding risk profiles to efficacy and safety of dabigatran dual therapy versus warfarin triple therapy in atrial fibrillation after percutaneous coronary intervention: An ancillary analysis from the RE-DUAL PCI trial.
    Am Heart J. 2019;212:13-22.
    >> Share

  259. FRIGOLI E, Smits P, Vranckx P, Ozaki Y, et al
    Design and rationale of the Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Standard DAPT Regimen (MASTER DAPT) Study.
    Am Heart J. 2019;209:97-105.
    >> Share

    February 2019
  260. BULLUCK H, Frohlich GM, Nicholas JM, Mohdnazri S, et al
    Mineralocorticoid receptor antagonist pre-treatment and early post-treatment to minimize reperfusion injury after ST-elevation myocardial infarction: The MINIMIZE STEMI trial.
    Am Heart J. 2019;211:60-67.
    >> Share

  261. FINN MT, Redfors B, Karmpaliotis D, Kirtane AJ, et al
    Adverse events in patients with high platelet reactivity following successful chronic total occlusion PCI: The Assessment of Dual AntiPlatelet Therapy with Drug-Eluting Stents (ADAPT-DES) study.
    Am Heart J. 2019;211:68-76.
    >> Share

  262. TANG X, Zhang D, He L, Wu N, et al
    Performance of atherosclerotic cardiovascular risk prediction models in a rural Northern Chinese population: Results from the Fangshan Cohort Study.
    Am Heart J. 2019;211:34-44.
    >> Share

    January 2019
  263. BLAKE SR, Shahzad A, Aggarwal SK, Kumar A, et al
    Radial versus femoral vascular access in ST-elevation myocardial infarction: Are the results of femoral operators unfairly represented in observational research?
    Am Heart J. 2019;210:81-87.
    >> Share

  264. HERTZ JT, Madut DB, Tesha RA, William G, et al
    Knowledge of myocardial infarction symptoms and perceptions of self-risk in Tanzania.
    Am Heart J. 2019;210:69-74.
    >> Share

  265. FERRARI R, Ford I, Fox K, Marzilli M, et al
    A randomized, double-blind, placebo-controlled trial to assess the efficAcy and safety of Trimetazidine in patients with angina pectoris having been treated by percutaneous coronary intervention (ATPCI study): Rationale, design, and baseline character
    Am Heart J. 2019;210:98-107.
    >> Share

  266. KOSMIDOU I, Redfors B, Chen S, Crowley A, et al
    C-reactive protein and prognosis after percutaneous coronary intervention and bypass graft surgery for left main coronary artery disease: Analysis from the EXCEL trial.
    Am Heart J. 2019;210:49-57.
    >> Share

  267. ALVI RM, Afshar M, Neilan AM, Tariq N, et al
    Heart failure and adverse heart failure outcomes among persons living with HIV in a US tertiary medical center.
    Am Heart J. 2019;210:39-48.
    >> Share

  268. YEBYO HG, Aschmann HE, Kaufmann M, Puhan MA, et al
    Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: A systematic review, meta-analysis, and network meta-analysis of randomized trials with 94,283 participants.
    Am Heart J. 2019;210:18-28.
    >> Share

    December 2018
  269. DESCH S, Freund A, Graf T, Fichtlscherer S, et al
    Immediate unselected coronary angiography versus delayed triage in survivors of out-of-hospital cardiac arrest without ST-segment elevation: Design and rationale of the TOMAHAWK trial.
    Am Heart J. 2018;209:20-28.
    >> Share

  270. IBRAHIM NE, McCarthy CP, Shrestha S, Lyass A, et al
    Blood kidney injury molecule-1 predicts short and longer term kidney outcomes in patients undergoing diagnostic coronary and/or peripheral angiography-Results from the Catheter Sampled Blood Archive in Cardiovascular Diseases (CASABLANCA) study.
    Am Heart J. 2018;209:36-46.
    >> Share

  271. WANG X, Tian M, Zheng Z, Gao H, et al
    Rationale and design of a multicenter randomized trial to compare the graft patency between no-touch vein harvesting technique and conventional approach in coronary artery bypass graft surgery.
    Am Heart J. 2018;210:75-80.
    >> Share

  272. FORDYCE CB, Chen AY, Wang TY, Lucas J, et al
    Patterns of use of targeted temperature management for acute myocardial infarction patients following out-of-hospital cardiac arrest: Insights from the National Cardiovascular Data Registry.
    Am Heart J. 2018;206:131-133.
    >> Share

    November 2018
  273. GIBSON CM, Kerneis M, Yee MK, Daaboul Y, et al
    The CSL112-2001 trial: Safety and tolerability of multiple doses of CSL112 (apolipoprotein A-I [human]), an intravenous formulation of plasma-derived apolipoprotein A-I, among subjects with moderate renal impairment after acute myocardial infarction.
    Am Heart J. 2018;208:81-90.
    >> Share

  274. DOLL JA, Hellkamp AS, Thomas L, Fonarow GC, et al
    The association of pre- and posthospital medication adherence in myocardial infarction patients.
    Am Heart J. 2018;208:74-80.
    >> Share

  275. HEAD T, Henn L, Andreev VP, Herderick EE, et al
    Accelerated coronary atherosclerosis not explained by traditional risk factors in 13% of young individuals.
    Am Heart J. 2018;208:47-54.
    >> Share

  276. PAGIDIPATI NJ, Coles A, Hemal K, Lee KL, et al
    Sex differences in management and outcomes of patients with stable symptoms suggestive of coronary artery disease: Insights from the PROMISE trial.
    Am Heart J. 2018;208:28-36.
    >> Share

  277. POLCWIARTEK C, Behrndtz P, Andersen AH, Bregendahl M, et al
    Attitudes and considerations of patients with ST-elevation myocardial infarction toward participation in randomized clinical trials.
    Am Heart J. 2018;208:21-27.
    >> Share

  278. HELD C, White HD, Stewart RAH, Davies R, et al
    Characterization of cardiovascular clinical events and impact of event adjudication on the treatment effect of darapladib versus placebo in patients with stable coronary heart disease: Insights from the STABILITY trial.
    Am Heart J. 2018;208:65-73.
    >> Share

  279. TRAN HV, Ash AS, Gore JM, Darling CE, et al
    Twenty-five year trends (1986-2011) in hospital incidence and case-fatality rates of ventricular tachycardia and ventricular fibrillation complicating acute myocardial infarction.
    Am Heart J. 2018;208:1-10.
    >> Share

    October 2018
  280. LAMBRAKIS K, French JK, Scott IA, Briffa T, et al
    The appropriateness of coronary investigation in myocardial injury and type 2 myocardial infarction (ACT-2): A randomized trial design.
    Am Heart J. 2018;208:11-20.
    >> Share

  281. MUNKHAUGEN J, Ruddox V, Halvorsen S, Dammen T, et al
    BEtablocker Treatment After acute Myocardial Infarction in revascularized patients without reduced left ventricular ejection fraction (BETAMI): Rationale and design of a prospective, randomized, open, blinded end point study.
    Am Heart J. 2018;208:37-46.
    >> Share

  282. MACHLINE-CARRION MJ, Soares RM, Damiani LP, Campos VB, et al
    Rationale and design for a cluster randomized quality-improvement trial to increase the uptake of evidence-based therapies for patients at high cardiovascular risk: The BRIDGE-Cardiovascular Prevention trial.
    Am Heart J. 2018;207:40-48.
    >> Share

  283. PAGIDIPATI NJ, Mudrick DW, Chiswell K, Brucker A, et al
    Sex differences in long-term outcomes of patients across the spectrum of coronary artery disease.
    Am Heart J. 2018;206:51-60.
    >> Share

    September 2018
  284. PRADHAN AD, Paynter NP, Everett BM, Glynn RJ, et al
    Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study.
    Am Heart J. 2018;206:80-93.
    >> Share

  285. GUEDENEY P, Baber U, Claessen B, Aquino M, et al
    Temporal trends, determinants, and impact of high-intensity statin prescriptions after percutaneous coronary intervention: Results from a large single-center prospective registry.
    Am Heart J. 2018;207:10-18.
    >> Share

  286. HARRISON RW, Radhakrishnan V, Allen JC Jr, Lam PS, et al
    The East-West late lumen loss study: Comparison of angiographic late lumen loss between Eastern and Western drug-eluting stent study cohorts.
    Am Heart J. 2018;206:61-71.
    >> Share

  287. CANNON CP, McGuire DK, Pratley R, Dagogo-Jack S, et al
    Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV).
    Am Heart J. 2018;206:11-23.
    >> Share

    August 2018
  288. ELGENDY IY, Mansoor H, Li Q, Guo Y, et al
    Long-term mortality and estimated functional capacity among women with symptoms of ischemic heart disease: From the NHLBI-sponsored Women's Ischemia Syndrome Evaluation.
    Am Heart J. 2018 Aug 30. pii: S0002-8703(18)30252.
    >> Share

  289. LEE J, Nakanishi R, Li D, Shaikh K, et al
    Randomized trial of rivaroxaban versus warfarin in the evaluation of progression of coronary atherosclerosis.
    Am Heart J. 2018 Aug 24. pii: S0002-8703(18)30249.
    >> Share

  290. ALFONSO F, Cuesta J, Garcia-Guimaraes M, Gonzalez-Barthol E, et al
    Treatment of patients with restenosis of drug-eluting stents.
    Am Heart J. 2018 Aug 24. pii: S0002-8703(18)30250.
    >> Share

  291. KANG DY, Wong YTA, Park DW, Park SJ, et al
    The authors reply: Treatment of patients with restenosis of drug-eluting stents.
    Am Heart J. 2018 Aug 23. pii: S0002-8703(18)30251.
    >> Share

  292. MAURI L, Kirtane AJ, Windecker S, Yeh RW, et al
    Rationale and design of the EVOLVE Short DAPT Study to assess 3-month dual antiplatelet therapy in subjects at high risk for bleeding undergoing percutaneous coronary intervention.
    Am Heart J. 2018;205:110-117.
    >> Share

  293. EINDHOVEN DC, Wu HW, Kremer SWF, van Erkelens JA, et al
    Mortality differences in acute myocardial infarction patients in the Netherlands: The weekend-effect.
    Am Heart J. 2018;205:70-76.
    >> Share

  294. CHUNG CJ, Kirtane AJ, Zhang Y, Witzenbichler B, et al
    Impact of high on-aspirin platelet reactivity on outcomes following successful percutaneous coronary intervention with drug-eluting stents.
    Am Heart J. 2018;205:77-86.
    >> Share

  295. LAURSEN PN, Holmvang L, Lonborg J, Kober L, et al
    Comparison between patients included in randomized controlled trials of ischemic heart disease and real-world data. A nationwide study.
    Am Heart J. 2018;204:128-138.
    >> Share

  296. MACK MJ, Abraham WT, Lindenfeld J, Bolling SF, et al
    Cardiovascular Outcomes Assessment of the MitraClip in Patients with Heart Failure and Secondary Mitral Regurgitation: Design and rationale of the COAPT trial.
    Am Heart J. 2018;205:1-11.
    >> Share

    July 2018
  297. BURGESS SN, French JK, Nguyen TL, Leung M, et al
    The impact of incomplete revascularization on early and late outcomes in ST-elevation myocardial infarction.
    Am Heart J. 2018;205:31-41.
    >> Share

  298. PAGIDIPATI NJ, Hellkamp AS, Sharma PP, Wang TY, et al
    High-sensitivity C-reactive protein elevation in patients with prior myocardial infarction in the United States.
    Am Heart J. 2018;204:151-155.
    >> Share

  299. MORICI N, Oliva F, Ajello S, Stucchi M, et al
    Management of cardiogenic shock in acute decompensated chronic heart failure: The ALTSHOCK phase II clinical trial.
    Am Heart J. 2018 Jul 20. pii: S0002-8703(18)30217.
    >> Share

  300. STEVENS ER, Farrell D, Jumkhawala SA, Ladapo JA, et al
    Quality of health economic evaluations for the ACC/AHA stable ischemic heart disease practice guideline: A systematic review.
    Am Heart J. 2018;204:17-33.
    >> Share

  301. GIBBONS RJ, Weintraub WS, Brindis RG
    Moving from volume to value for revascularization in stable ischemic heart disease: A review.
    Am Heart J. 2018 Jul 10. pii: S0002-8703(18)30108.
    >> Share

  302. HUGELSHOFER S, Roffi M, Witassek F, Eberli FR, et al
    Impact of total ischemic time on manual thrombus aspiration benefit during primary percutaneous coronary intervention.
    Am Heart J. 2018;204:34-42.
    >> Share

  303. GUALANDRO DM, Puelacher C, LuratiBuse G, Lampart A, et al
    Comparison of high-sensitivity cardiac troponin I and T for the prediction of cardiac complications after non-cardiac surgery.
    Am Heart J. 2018;203:67-73.
    >> Share

  304. GNANENTHIRAN SR, Yiannikas J, Lowe HC, Brieger D, et al
    Aspirin hypersensitivity in patients with coronary artery disease: linking pathophysiology to clinical practice.
    Am Heart J. 2018;203:74-81.
    >> Share

  305. RYMER JA, Tempelhof MW, Clare RM, Pieper KS, et al
    Discharge timing and outcomes after uncomplicated non-ST-segment elevation acute myocardial infarction.
    Am Heart J. 2018;201:103-110.
    >> Share

  306. VENETSANOS D, Lawesson SS, James S, Koul S, et al
    Bivalirudin versus heparin with primary percutaneous coronary intervention.
    Am Heart J. 2018;201:9-16.
    >> Share

  307. INOHARA T, Pieper K, Wojdyla DM, Patel MR, et al
    Incidence, timing, and type of first and recurrent ischemic events in patients with and without peripheral artery disease after an acute coronary syndrome.
    Am Heart J. 2018;201:25-32.
    >> Share

    June 2018
  308. XU H, Faxen J, Szummer K, Trevisan M, et al
    Dyskalemias and adverse events associated with discharge potassium in acute myocardial infarction.
    Am Heart J. 2018;205:53-62.
    >> Share

  309. CHI G, Kerneis M, Kalayci A, Liu Y, et al
    Safety and efficacy of non-vitamin K oral anticoagulant for atrial fibrillation patients after percutaneous coronary intervention: A bivariate analysis of the PIONEER AF-PCI and RE-DUAL PCI trial.
    Am Heart J. 2018;203:17-24.
    >> Share

  310. PAOLI G, Notarangelo MF, Mattioli M, La Sala R, et al
    ALLiance for sEcondary PREvention after an acute coronary syndrome. The ALLEPRE trial: A multicenter fully nurse-coordinated intensive intervention program.
    Am Heart J. 2018;203:12-16.
    >> Share

  311. GREEN JB, Hernandez AF, D'Agostino RB, Granger CB, et al
    Harmony Outcomes: A randomized, double-blind, placebo-controlled trial of the effect of albiglutide on major cardiovascular events in patients with type 2 diabetes mellitus-Rationale, design, and baseline characteristics.
    Am Heart J. 2018;203:30-38.
    >> Share

  312. ATZEMA CL, Dorian P, Fang J, Tu JV, et al
    A clinical decision instrument to predict 30-day death and cardiovascular hospitalizations after an emergency department visit for atrial fibrillation: The Atrial Fibrillation in the Emergency Room, Part 2 (AFTER2) study.
    Am Heart J. 2018;203:85-92.
    >> Share

  313. HJORT M, Lindahl B, Baron T, Jernberg T, et al
    Prognosis in relation to high-sensitivity cardiac troponin T levels in patients with myocardial infarction and non-obstructive coronary arteries.
    Am Heart J. 2018;200:60-66.
    >> Share

  314. ISRAR MZ, Heaney LM, Ng LL, Suzuki T, et al
    B-type natriuretic peptide molecular forms for risk stratification and prediction of outcome after acute myocardial infarction.
    Am Heart J. 2018;200:37-43.
    >> Share

  315. CAPLICE NM, DeVoe MC, Choi J, Dahly D, et al
    Randomized placebo controlled trial evaluating the safety and efficacy of single low-dose intracoronary insulin-like growth factor following percutaneous coronary intervention in acute myocardial infarction (RESUS-AMI).
    Am Heart J. 2018;200:110-117.
    >> Share

  316. CARSON JL, Stanworth SJ, Alexander JH, Roubinian N, et al
    Clinical trials evaluating red blood cell transfusion thresholds: An updated systematic review and with additional focus on patients with cardiovascular disease.
    Am Heart J. 2018;200:96-101.
    >> Share

  317. ELFWEN L, Lagedal R, James S, Jonsson M, et al
    Coronary angiography in out-of-hospital cardiac arrest without ST elevation on ECG-Short- and long-term survival.
    Am Heart J. 2018;200:90-95.
    >> Share

  318. WIVIOTT SD, Raz I, Bonaca MP, Mosenzon O, et al
    The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 Trial.
    Am Heart J. 2018;200:83-89.
    >> Share

  319. LATTUCA B, Barber-Chamoux N, Alos B, Sfaxi A, et al
    Impact of video on the understanding and satisfaction of patients receiving informed consent before elective inpatient coronary angiography: A randomized trial.
    Am Heart J. 2018;200:67-74.
    >> Share

  320. PASTORI D, Pignatelli P, Cribari F, Carnevale R, et al
    Time to therapeutic range (TtTR), anticoagulation control, and cardiovascular events in vitamin K antagonists-naive patients with atrial fibrillation.
    Am Heart J. 2018;200:32-36.
    >> Share

  321. LOPES RD, Vora AN, Liaw D, Granger CB, et al
    An open-Label, 2 x 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention:
    Am Heart J. 2018;200:17-23.
    >> Share

    May 2018
  322. ITSIOPOULOS C, Kucianski T, Mayr HL, van Gaal WJ, et al
    The AUStralian MEDiterranean Diet Heart Trial (AUSMED Heart Trial): A randomized clinical trial in secondary prevention of coronary heart disease in a multiethnic Australian population: Study protocol.
    Am Heart J. 2018;203:4-11.
    >> Share

  323. VARDENY O, Udell JA, Joseph J, Farkouh ME, et al
    High-dose influenza vaccine to reduce clinical outcomes in high-risk cardiovascular patients: Rationale and design of the INVESTED trial.
    Am Heart J. 2018;202:97-103.
    >> Share

  324. HOLMEN J, Herlitz J, Axelsson C
    Immediate coronary intervention in prehospital cardiac arrest-Aiming to save lives.
    Am Heart J. 2018 May 22. pii: S0002-8703(18)30158.
    >> Share

  325. LI S, Blumenthal JA, Shi C, Millican D, et al
    I-CARE randomized clinical trial integrating depression and acute coronary syndrome care in low-resource hospitals in China: Design and rationale.
    Am Heart J. 2018;202:109-115.
    >> Share

  326. JAKOBSEN L, Christiansen EH, Maeng M, Kristensen SD, et al
    Randomized clinical comparison of the dual-therapy CD34 antibody-covered sirolimus-eluting Combo stent with the sirolimus-eluting Orsiro stent in patients treated with percutaneous coronary intervention: Rationale and study design of the Scandinavian
    Am Heart J. 2018;202:49-53.
    >> Share

  327. HSU S, Kambhampati S, Sciortino CM, Russell SD, et al
    Predictors of intra-aortic balloon pump hemodynamic failure in non-acute myocardial infarction cardiogenic shock.
    Am Heart J. 2018;199:181-191.
    >> Share

  328. WANG A, Wu A, Wojdyla D, Lopes RD, et al
    Dual antiplatelet therapy for perioperative myocardial infarction following CABG surgery.
    Am Heart J. 2018;199:150-155.
    >> Share

  329. GIANOS E, Schoenthaler A, Guo Y, Zhong J, et al
    Investigation of Motivational Interviewing and Prevention Consults to Achieve Cardiovascular Targets (IMPACT) trial.
    Am Heart J. 2018;199:37-43.
    >> Share

  330. BRINKLEY DM JR, Ho KKL, Drazner MH, Kociol RD, et al
    The prognostic value of the relationship between right atrial and pulmonary capillary wedge pressure in diverse cardiovascular conditions.
    Am Heart J. 2018;199:31-36.
    >> Share

  331. MARWICK TH, Whitmore K, Nicholls SJ, Stanton T, et al
    Rationale and design of a trial to personalize risk assessment in familial coronary artery disease.
    Am Heart J. 2018;199:22-30.
    >> Share

  332. THEODORAKIS MJ, Coleman RL, Feng H, Chan J, et al
    Baseline characteristics and temporal differences in Acarbose Cardiovascular Evaluation (ACE) trial participants.
    Am Heart J. 2018;199:170-175.
    >> Share

  333. LACHMAN S, Terbraak MS, Limpens J, Jorstad H, et al
    The prognostic value of heart rate recovery in patients with coronary artery disease: A systematic review and meta-analysis.
    Am Heart J. 2018;199:163-169.
    >> Share

  334. GHARACHOLOU SM, Ijioma NN, Lennon RJ, Rihal CS, et al
    Characteristics and long term outcomes of patients with acute coronary syndromes due to culprit left main coronary artery disease treated with percutaneous coronary intervention.
    Am Heart J. 2018;199:156-162.
    >> Share

  335. YAO X, Gersh BJ, Sangaralingham LR, Shah ND, et al
    Risk of cardiovascular events and incident atrial fibrillation in patients without prior atrial fibrillation: Implications for expanding the indications for anticoagulation.
    Am Heart J. 2018;199:137-143.
    >> Share

  336. BOSWORTH HB, Olsen MK, McCant F, Stechuchak KM, et al
    Telemedicine cardiovascular risk reduction in veterans: The CITIES trial.
    Am Heart J. 2018;199:122-129.
    >> Share

  337. KANG J, Koo BK, Hu X, Lee JM, et al
    Comparison of Fractional FLow Reserve And Intravascular ultrasound-guided Intervention Strategy for Clinical OUtcomes in Patients with InteRmediate Stenosis (FLAVOUR): Rationale and design of a randomized clinical trial.
    Am Heart J. 2018;199:7-12.
    >> Share

  338. VETROVEC GW, Anderson M, Schreiber T, Popma J, et al
    The cVAD registry for percutaneous temporary hemodynamic support: A prospective registry of Impella mechanical circulatory support use in high-risk PCI, cardiogenic shock, and decompensated heart failure.
    Am Heart J. 2018;199:115-121.
    >> Share

    April 2018
  339. PATEL KK, Arnold SV, Chan PS, Tang Y, et al
    Validation of the Seattle angina questionnaire in women with ischemic heart disease.
    Am Heart J. 2018;201:117-123.
    >> Share

  340. SPRUILL TM, Reynolds HR, Dickson VV, Shallcross AJ, et al
    Telephone-based mindfulness training to reduce stress in women with myocardial infarction: Rationale and design of a multicenter randomized controlled trial.
    Am Heart J. 2018;202:61-67.
    >> Share

  341. O'NEILL WW, Grines C, Schreiber T, Moses J, et al
    Analysis of outcomes for 15,259 US patients with acute myocardial infarction cardiogenic shock (AMICS) supported with the Impella device.
    Am Heart J. 2018;202:33-38.
    >> Share

  342. PENNY WF, Henry TD, Watkins MW, Patel AN, et al
    Design of a Phase 3 trial of intracoronary administration of human adenovirus 5 encoding human adenylyl cyclase type 6 (RT-100) gene transfer in patients with heart failure with reduced left ventricular ejection fraction: The FLOURISH Clinical Trial.
    Am Heart J. 2018;201:111-116.
    >> Share

  343. MUHLESTEIN JB, May HT, Galenko O, Knowlton KU, et al
    GlycA and hsCRP are independent and additive predictors of future cardiovascular events among patients undergoing angiography: The intermountain heart collaborative study.
    Am Heart J. 2018;202:27-32.
    >> Share

  344. RAVAL AN, Cook TD, Duckers HJ, Johnston PV, et al
    The CardiAMP Heart Failure trial: A randomized controlled pivotal trial of high-dose autologous bone marrow mononuclear cells using the CardiAMP cell therapy system in patients with post-myocardial infarction heart failure: Trial rationale and study d
    Am Heart J. 2018;201:141-148.
    >> Share

  345. FORD TJ, Corcoran D, Oldroyd KG, McEntegart M, et al
    Rationale and design of the British Heart Foundation (BHF) Coronary Microvascular Angina (CorMicA) stratified medicine clinical trial.
    Am Heart J. 2018;201:86-94.
    >> Share

  346. RYMER JA, Kaltenbach LA, Anstrom KJ, Fonarow GC, et al
    Hospital evaluation of health literacy and associated outcomes in patients after acute myocardial infarction.
    Am Heart J. 2018;198:97-107.
    >> Share

  347. CHEW DS, Wilton SB, Kavanagh K, Southern DA, et al
    Left ventricular ejection fraction reassessment post-myocardial infarction: Current clinical practice and determinants of adverse remodeling.
    Am Heart J. 2018;198:91-96.
    >> Share

  348. KINNAIRD T, Cockburn J, Gallagher S, Choudhury A, et al
    Temporal changes in radial access use, associates and outcomes in patients undergoing PCI using rotational atherectomy between 2007 and 2014: results from the British Cardiovascular Intervention Society national database.
    Am Heart J. 2018;198:46-54.
    >> Share

  349. CACOUB P, Nahon P, Layese R, Blaise L, et al
    Prognostic value of viral eradication for major adverse cardiovascular events in hepatitis C cirrhotic patients.
    Am Heart J. 2018;198:4-17.
    >> Share

  350. BISHAWI M, Hattler B, Almassi GH, Spertus JA, et al
    Preoperative factors associated with worsening in health-related quality of life following coronary artery bypass grafting in the Randomized On/Off Bypass (ROOBY) trial.
    Am Heart J. 2018;198:33-38.
    >> Share

  351. AL RIFAI M, Greenland P, Blaha MJ, Michos ED, et al
    Factors of health in the protection against death and cardiovascular disease among adults with subclinical atherosclerosis.
    Am Heart J. 2018;198:180-188.
    >> Share

  352. NAVAR AM, Pencina MJ, Mulder H, Elias P, et al
    Improving patient risk communication: Translating cardiovascular risk into standardized risk percentiles.
    Am Heart J. 2018;198:18-24.
    >> Share

  353. TOMASELLI G, Roach WH, Pina IL, Oster ME, et al
    Government continues to have an important role in promoting cardiovascular health.
    Am Heart J. 2018;198:160-165.
    >> Share

  354. BOWMAN L, Mafham M, Stevens W, Haynes R, et al
    ASCEND: A Study of Cardiovascular Events iN Diabetes: Characteristics of a randomized trial of aspirin and of omega-3 fatty acid supplementation in 15,480 people with diabetes.
    Am Heart J. 2018;198:135-144.
    >> Share

  355. BATCHELOR W, Dahya V, McGee D, Katopodis J, et al
    Ultrahigh-resolution ultrasound characterization of access site trauma and intimal hyperplasia following use of a 7F sheathless guide versus 6F sheath/guide combination for transradial artery PCI: Results of the PRAGMATIC trial.
    Am Heart J. 2018;198:75-83.
    >> Share

  356. VAN DER HEIJDEN LC, Kok MM, Zocca P, Jessurun GAJ, et al
    Bioresorbable Polymer-Coated Orsiro Versus Durable Polymer-Coated Resolute Onyx Stents (BIONYX): Rationale and design of the randomized TWENTE IV multicenter trial.
    Am Heart J. 2018;198:25-32.
    >> Share

  357. BERGMEIJER TO, Reny JL, Pakyz RE, Gong L, et al
    Genome-wide and candidate gene approaches of clopidogrel efficacy using pharmacodynamic and clinical end points-Rationale and design of the International Clopidogrel Pharmacogenomics Consortium (ICPC).
    Am Heart J. 2018;198:152-159.
    >> Share

  358. BERWANGER O, de Barros E Silva PGM, Dall Orto FTC, de Andrade PB, et al
    Rationale and design of the Statins Evaluation in Coronary procedUres and REvascularization: The SECURE-PCI Trial.
    Am Heart J. 2018;198:129-134.
    >> Share

    March 2018
  359. BOHULA EA, Scirica BM, Fanola C, Inzucchi SE, et al
    Design and rationale for the Cardiovascular and Metabolic Effects of Lorcaserin in Overweight and Obese Patients-Thrombolysis in Myocardial Infarction 61 (CAMELLIA-TIMI 61) trial.
    Am Heart J. 2018;202:39-48.
    >> Share

  360. BERWANGER O, Nicolau JC, Carvalho AC, Jiang L, et al
    Ticagrelor versus clopidogrel after fibrinolytic therapy in patients with ST-elevation myocardial infarction: Rationale and design of the ticagrelor in patients with ST elevation myocardial infarction treated with thrombolysis (TREAT) trial.
    Am Heart J. 2018;202:89-96.
    >> Share

  361. LOOP MS, McClure LA, Levitan EB, Al-Hamdan MZ, et al
    Fine particulate matter and incident coronary heart disease in the REGARDS cohort.
    Am Heart J. 2018;197:94-102.
    >> Share

  362. SHAVADIA JS, French W, Hellkamp AS, Thomas L, et al
    Comprehensive electrocardiogram-to-device time for primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: A report from the American Heart Association mission: Lifeline program.
    Am Heart J. 2018;197:9-17.
    >> Share

  363. HAYS AG, Iantorno M, Schar M, Lai S, et al
    The influence of febuxostat on coronary artery endothelial dysfunction in patients with coronary artery disease: A phase 4 randomized, placebo-controlled, double-blind, crossover trial.
    Am Heart J. 2018;197:85-93.
    >> Share

  364. SONG YB, Oh SK, Oh JH, Im ES, et al
    Rationale and design of the comparison between a P2Y12 inhibitor monotherapy versus dual antiplatelet therapy in patients undergoing implantation of coronary drug-eluting stents (SMART-CHOICE): A prospective multicenter randomized trial.
    Am Heart J. 2018;197:77-84.
    >> Share

  365. EGGERS KM, Jernberg T, Lindahl B
    High-sensitivity cardiac troponin T, left ventricular function, and outcome in non-ST elevation acute coronary syndrome.
    Am Heart J. 2018;197:70-76.
    >> Share

  366. LAGEDAL R, Elfwen L, James S, Oldgren J, et al
    Design of DISCO-Direct or Subacute Coronary Angiography in Out-of-Hospital Cardiac Arrest study.
    Am Heart J. 2018;197:53-61.
    >> Share

  367. WONG YTA, Kang DY, Lee JB, Rha SW, et al
    Comparison of drug-eluting stents and drug-coated balloon for the treatment of drug-eluting coronary stent restenosis: A randomized RESTORE trial.
    Am Heart J. 2018;197:35-42.
    >> Share

  368. REDFORS B, Genereux P, Witzenbichler B, Maehara A, et al
    Percutaneous coronary intervention of lesions with in-stent restenosis: A report from the ADAPT-DES study.
    Am Heart J. 2018;197:142-149.
    >> Share

  369. KOPIN D, Jones WS, Sherwood MW, Wojdyla DM, et al
    Percutaneous coronary intervention and antiplatelet therapy in patients with atrial fibrillation receiving apixaban or warfarin: Insights from the ARISTOTLE trial.
    Am Heart J. 2018;197:133-141.
    >> Share

  370. HWANG D, Park KW, Lee JM, Rhee TM, et al
    Efficacy and safety of dual antiplatelet therapy after coronary stenting in patients with chronic kidney disease.
    Am Heart J. 2018;197:103-112.
    >> Share

  371. SHERWOOD MW, Lopes RD, Sun JL, Liaw D, et al
    Apixaban following acute coronary syndromes in patients with prior stroke: Insights from the APPRAISE-2 trial.
    Am Heart J. 2018;197:1-8.
    >> Share

  372. CZARNY MJ, Miller JM, Naiman DQ, Hwang CW, et al
    Nonprimary PCI at hospitals without cardiac surgery on-site: Consistent outcomes for all?
    Am Heart J. 2018;197:18-26.
    >> Share

    February 2018
  373. LENG WX, Yang J, Li W, Wang Y, et al
    Rationale and design of the DEAR-OLD trial: Randomized evaluation of routinely Deferred versus EARly invasive strategy in elderly patients of 75 years or OLDer with non-ST-elevation myocardial infarction.
    Am Heart J. 2018;196:65-73.
    >> Share

  374. BAGAI A, Goodman SG, Cantor WJ, Vicaut E, et al
    Duration of ischemia and treatment effects of pre- versus in-hospital ticagrelor in patients with ST-segment elevation myocardial infarction: Insights from the ATLANTIC study.
    Am Heart J. 2018;196:56-64.
    >> Share

  375. GUIMARAES PO, Leonardi S, Huang Z, Wallentin L, et al
    Clinical features and outcomes of patients with type 2 myocardial infarction: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial.
    Am Heart J. 2018;196:28-35.
    >> Share

  376. KILIC S, Fabris E, Van't Hof AWJ, Hamm CW, et al
    Thrombus aspiration and prehospital ticagrelor administration in ST-elevation myocardial infarction: Findings from the ATLANTIC trial.
    Am Heart J. 2018;196:1-8.
    >> Share

  377. DUPRE ME, Xu H, Granger BB, Lynch SM, et al
    Access to routine care and risks for 30-day readmission in patients with cardiovascular disease.
    Am Heart J. 2018;196:9-17.
    >> Share

  378. MCCARTHY CP, McEvoy JW, Januzzi JL Jr.
    Biomarkers in stable coronary artery disease.
    Am Heart J. 2018;196:82-96.
    >> Share

  379. ANYANWAGU U, Mamza J, Donnelly R, Idris I, et al
    Effect of adding GLP-1RA on mortality, cardiovascular events, and metabolic outcomes among insulin-treated patients with type 2 diabetes: A large retrospective UK cohort study.
    Am Heart J. 2018;196:18-27.
    >> Share

  380. KHAZANIE P, Al-Khatib SM, Wang TY, Crowley MJ, et al
    Training cardiovascular outcomes researchers: A survey of mentees and mentors to identify critical training gaps and needs.
    Am Heart J. 2018;196:170-177.
    >> Share

  381. CROWLEY MJ, Al-Khatib SM, Wang TY, Khazanie P, et al
    How well does early-career investigators' cardiovascular outcomes research training align with funded outcomes research?
    Am Heart J. 2018;196:163-169.
    >> Share

  382. VRANCKX P, Lewalter T, Valgimigli M, Tijssen JG, et al
    Evaluation of the safety and efficacy of an edoxaban-based antithrombotic regimen in patients with atrial fibrillation following successful percutaneous coronary intervention (PCI) with stent placement: Rationale and design of the ENTRUST-AF PCI trial
    Am Heart J. 2018;196:105-112.
    >> Share

  383. LAURIDSEN KG, Schmidt AS, Adelborg K, Bach L, et al
    Effects of hyperoxia on myocardial injury following cardioversion-A randomized clinical trial.
    Am Heart J. 2018;196:97-104.
    >> Share

  384. SCIAHBASI A, Frigoli E, Sarandrea A, Calabro P, et al
    Determinants of radiation dose during right transradial access: Insights from the RAD-MATRIX study.
    Am Heart J. 2018;196:113-118.
    >> Share

    January 2018
  385. AFANA M, Gurm HS, Seth M, Frazier KM, et al
    Primary percutaneous coronary intervention at centers with and without on-site surgical support: Insights from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2).
    Am Heart J. 2018;195:99-107.
    >> Share

  386. TARANTINI G, Ueshima D, D'Amico G, Masiero G, et al
    Efficacy and safety of potent platelet P2Y12 receptor inhibitors in elderly versus nonelderly patients with acute coronary syndrome: A systematic review and meta-analysis.
    Am Heart J. 2018;195:78-85.
    >> Share

  387. ISSA OM, Roberts R, Mark DB, Boineau R, et al
    Effect of high-dose oral multivitamins and minerals in participants not treated with statins in the randomized Trial to Assess Chelation Therapy (TACT).
    Am Heart J. 2018;195:70-77.
    >> Share

  388. BOSSARD M, Binbraik Y, Beygui F, Pitt B, et al
    Mineralocorticoid receptor antagonists in patients with acute myocardial infarction - A systematic review and meta-analysis of randomized trials.
    Am Heart J. 2018;195:60-69.
    >> Share

  389. LIU E, Hsueh L, Kim H, Vidovich MI, et al
    Global geographical variation in patient characteristics in percutaneous coronary intervention clinical trials: A systematic review and meta-analysis.
    Am Heart J. 2018;195:39-49.
    >> Share

  390. HESS PL, Kennedy K, Cowherd M, Virani SS, et al
    Implications of the FDA approval of PCSK9 inhibitors and FOURIER results for contemporary cardiovascular practice: An NCDR Research to Practice (R2P) project.
    Am Heart J. 2018;195:151-152.
    >> Share

  391. VEMULAPALLI S, Holmes DR Jr, Dai D, Matsouaka R, et al
    Valve hemodynamic deterioration and cardiovascular outcomes in TAVR: A report from the STS/ACC TVT Registry.
    Am Heart J. 2018;195:1-13.
    >> Share

    December 2017
  392. ILIESCU CA, Cilingiroglu M, Giza DE, Rosales O, et al
    "Bringing on the light" in a complex clinical scenario: Optical coherence tomography-guided discontinuation of antiplatelet therapy in cancer patients with coronary artery disease (PROTECT-OCT registry).
    Am Heart J. 2017;194:83-91.
    >> Share

  393. QADERDAN K, Vos GA, McAndrew T, Steg PG, et al
    Outcomes in elderly and young patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with bivalirudin versus heparin: Pooled analysis from the EUROMAX and HORIZONS-AMI trials.
    Am Heart J. 2017;194:73-82.
    >> Share

  394. INOHARA T, Numasawa Y, Higashi T, Ueda I, et al
    Predictors of high cost after percutaneous coronary intervention: A review from Japanese multicenter registry overviewing the influence of procedural complications.
    Am Heart J. 2017;194:61-72.
    >> Share

  395. DESAI NR, Kennedy KF, Cohen DJ, Connolly T, et al
    Contemporary risk model for inhospital major bleeding for patients with acute myocardial infarction: The acute coronary treatment and intervention outcomes network (ACTION) registry(R)-Get With The Guidelines (GWTG)(R).
    Am Heart J. 2017;194:16-24.
    >> Share

  396. HIRJI SA, Stevens SR, Shaw LK, Campbell EC, et al
    Predicting risk of cardiac events among ST-segment elevation myocardial infarction patients with conservatively managed non-infarct-related artery coronary artery disease: An analysis of the Duke Databank for Cardiovascular Disease.
    Am Heart J. 2017;194:116-124.
    >> Share

  397. GO AS, Fan D, Sung SH, Inveiss AI, et al
    Contemporary rates and correlates of statin use and adherence in nondiabetic adults with cardiovascular risk factors: The KP CHAMP study.
    Am Heart J. 2017;194:25-38.
    >> Share

    November 2017
  398. MUSTO C, De Felice F, Rigattieri S, Chin D, et al
    Instantaneous wave-free ratio and fractional flow reserve for the assessment of nonculprit lesions during the index procedure in patients with ST-segment elevation myocardial infarction: The WAVE study.
    Am Heart J. 2017;193:63-69.
    >> Share

  399. RUSSO JJ, Goodman SG, Cantor WJ, Ko DT, et al
    Does renal function affect the efficacy or safety of a pharmacoinvasive strategy in patients with ST-elevation myocardial infarction? A meta-analysis.
    Am Heart J. 2017;193:46-54.
    >> Share

  400. AKINTOYE E, Briasoulis A, Afonso L
    Biochemical risk markers and 10-year incidence of atherosclerotic cardiovascular disease: independent predictors, improvement in pooled cohort equation, and risk reclassification.
    Am Heart J. 2017;193:95-103.
    >> Share

  401. LEE PH, Lee JY, Lee CW, Han S, et al
    Long-term outcomes of bypass grafting versus drug-eluting stenting for left main coronary artery disease: Results from the IRIS-MAIN registry.
    Am Heart J. 2017;193:76-83.
    >> Share

  402. DOROS G, Massaro JM, Kandzari DE, Waksman R, et al
    Rationale of a novel study design for the BIOFLOW V study, a prospective, randomized multicenter study to assess the safety and efficacy of the Orsiro sirolimus-eluting coronary stent system using a Bayesian approach.
    Am Heart J. 2017;193:35-45.
    >> Share

  403. CHIANG MH, Wu HH, Shih CJ, Chen YT, et al
    Association between influenza vaccination and reduced risks of major adverse cardiovascular events in elderly patients.
    Am Heart J. 2017;193:1-7.
    >> Share

  404. SHADDY R, Canter C, Halnon N, Kochilas L, et al
    Design for the sacubitril/valsartan (LCZ696) compared with enalapril study of pediatric patients with heart failure due to systemic left ventricle systolic dysfunction (PANORAMA-HF study).
    Am Heart J. 2017;193:23-34.
    >> Share

    October 2017
  405. WAKSMAN R, Torguson R, Spad MA, Garcia-Garcia H, et al
    The Lipid-Rich Plaque Study of vulnerable plaques and vulnerable patients: Study design and rationale.
    Am Heart J. 2017;192:98-104.
    >> Share

  406. JESSEE R, Peart E, Beineke P, Rosenberg S, et al
    Rheumatoid arthritis complicates noninvasive whole blood gene expression testing for coronary artery disease.
    Am Heart J. 2017;192:13-18.
    >> Share

  407. DEHGHANI P, Lavoie A, Lavi S, Crawford JJ, et al
    Effects of ticagrelor versus clopidogrel on platelet function in fibrinolytic-treated STEMI patients undergoing early PCI.
    Am Heart J. 2017;192:105-112.
    >> Share

  408. ALBERT MA, Durazo EM, Slopen N, Zaslavsky AM, et al
    Cumulative psychological stress and cardiovascular disease risk in middle aged and older women: Rationale, design, and baseline characteristics.
    Am Heart J. 2017;192:1-12.
    >> Share

    September 2017
  409. WALLERT J, Held C, Madison G, Olsson EM, et al
    Temporal changes in myocardial infarction incidence rates are associated with periods of perceived psychosocial stress: A SWEDEHEART national registry study.
    Am Heart J. 2017;191:12-20.
    >> Share

  410. GUDNADOTTIR GS, Andersen K, Thrainsdottir IS, James SK, et al
    Gender differences in coronary angiography, subsequent interventions, and outcomes among patients with acute coronary syndromes.
    Am Heart J. 2017;191:65-74.
    >> Share

  411. FARB A, Zuckerman BD
    Clinical event adjudication in cardiovascular device trials: An Food and Drug Administration perspective.
    Am Heart J. 2017;191:62-64.
    >> Share

  412. REN HY, Khera A, de Lemos JA, Ayers CR, et al
    Soluble endothelial cell-selective adhesion molecule and incident cardiovascular events in a multiethnic population.
    Am Heart J. 2017;191:55-61.
    >> Share

  413. KIM Y, Soffler M, Paradise S, Jelani QU, et al
    Depression is associated with recurrent chest pain with or without coronary artery disease: A prospective cohort study in the emergency department.
    Am Heart J. 2017;191:47-54.
    >> Share

  414. WEI J, Mehta PK, Grey E, Garberich RF, et al
    Sex-based differences in quality of care and outcomes in a health system using a standardized STEMI protocol.
    Am Heart J. 2017;191:30-36.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016